



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>C12N 15/86, 15/45, C07K 14/135, 14/115, A61K 31/70</b>	<b>A1</b>	(11) International Publication Number: <b>WO 99/25858</b> (43) International Publication Date: <b>27 May 1999 (27.05.99)</b>
--	-----------	---

(21) International Application Number: **PCT/CA98/01064**(22) International Filing Date: **13 November 1998 (13.11.98)**(30) Priority Data:  
**60/065,791** **14 November 1997 (14.11.97)** **US**(71) Applicant (for all designated States except US): **CONNAUGHT  
LABORATORIES LIMITED [CA/CA]; 1755 Steeles Av-  
enue West, North York, Ontario M2R 3T4 (CA).**

(72) Inventors; and

(75) Inventors/Applicants (for US only): **PARRINGTON, Mark  
[CA/CA]; 45 Martin Street, Bradford, Ontario L3Z 1Z4  
(CA). LI, Xiaomao [CN/CA]; 106 Glenmanor Way, Thorn-  
hill, Ontario L4J 3E5 (CA).**(74) Agent: **STEWART, Michael, I.; 6th floor, 330 University  
Avenue, Toronto, Ontario M5G 1R7 (CA).**(81) Designated States: **AL, AM, AT, AU, AZ, BA, BB, BG, BR,  
BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE,  
GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ,  
LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW,  
MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL,  
TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO  
patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European  
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR,  
IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF,  
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).****Published***With international search report.**Before the expiration of the time limit for amending the  
claims and to be republished in the event of the receipt of  
amendments.*(54) Title: **ALPHAVIRUS VECTORS FOR PARAMYXOVIRUS VACCINES****(57) Abstract**

A DNA vector comprises a first DNA sequence which is complementary to at least part of an alphavirus RNA genome and having the complement of complete alphavirus DNA genome replication regions, and a second DNA sequence encoding a paramyxovirus protein, particularly a respiratory syncytial virus fusion (RSV F) protein or a RSV F protein fragment that generates antibodies that specifically react with RSV F protein, the first and second DNA sequences being under the transcriptional control of a promoter, preferably a cytomegalovirus promoter, which may include Intron A. Such vectors also contain a further nucleotide sequence located between the promoter sequence and the alphavirus sequence to enhance the immunoprotective ability of the RSV F protein when expressed *in vivo*. Such DNA vectors may be used to immunize a host against disease caused by infection with RSV or other paramyxovirus, including a human host, by administration thereto, and may be formulated as immunogenic compositions with pharmaceutically-acceptable carriers for such purposes. Such vectors also may be used to produce antibodies for detection of RSV or other paramyxovirus infection in a sample.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

TITLE OF INVENTIONALPHAVIRUS VECTORS FOR PARAMYXOVIRUS VACCINES

5

FIELD OF INVENTION

The present invention relates to the field of paramyxoviridae vaccines and is particularly concerned with vaccines comprising DNA encoding the fusion (F) protein of respiratory syncytial virus (RSV) in an alphavirus vector.

BACKGROUND OF THE INVENTION

Human respiratory syncytial virus (RSV) has been identified as a major pathogen responsible for severe respiratory tract infections in infants, young children and the institutionalized elderly (refs. 1,2,3,4 - throughout this application, various references are cited in parentheses to describe more fully the state of the art to which this invention pertains. Full bibliographic information for each citation is found at the end of the specification, immediately preceding the claims. The disclosures of these references are hereby incorporated by reference into the present disclosure). Global mortality and morbidity figures indicate that there is an urgent need for an efficacious RSV vaccine (refs. 5,6). In the USA alone, approximately 100,000 children are hospitalized annually with severe cases of pneumonia and bronchiolitis resulting from an RSV infection. Inpatient and ambulatory care for children with RSV infections has been estimated to cost in excess of \$340 million each year in the USA. The World Health Organization (WHO) and the National Institute of Allergy and Infectious Disease (NIAID) vaccine advisory

committees have ranked RSV second only to HIV for vaccine development. Both the annual morbidity and mortality figures as well as the staggering health care costs for managing RSV infections have provided the incentive for aggressively pursuing the development of efficacious RSV vaccines. However, such a vaccine is still not available.

Formalin-inactivated (FI-RSV) and live attenuated RSV vaccines have failed to demonstrate efficacy in clinical trials (refs. 7,8,9,10). Moreover, the formalin-inactivated RSV vaccine caused enhanced disease in some children following exposure to wild-type RSV (refs. 7,8,9,10). Elucidation of the mechanism(s) involved in the potentiation of RSV disease is important for the design of safe RSV vaccines, especially for the seronegative population. Recent experimental evidence suggests that an imbalance in cell-mediated responses may contribute to immunopotential. Enhanced histopathology observed in mice that were immunized with the FI-RSV and challenged with virus could be abrogated by depletion of CD4+ cells or both interleukin-4 (IL-4) and IL-10.

The RSV fusion (F) glycoprotein is one of the major immunogenic proteins of the virus. This envelope glycoprotein mediates both fusion of the virus to the host cell membrane and cell-to-cell spread of the virus (ref. 1). The F protein is synthesized as a precursor ( $F_0$ ) molecule which is proteolytically cleaved to form a disulphide-linked dimer composed of the N-terminal  $F_2$  and C-terminal  $F_1$  moieties (ref. 11). The amino acid sequence of the F protein is highly conserved among RSV

subgroups A and B and is a cross-protective antigen (refs. 6,12). In the baculovirus expression system, a truncated secreted version of the RSV F protein has been expressed in *Trichoplusia ni* insect cells (ref. 13). The recombina<sup>5</sup>nt protein was demonstrated to be protective in the cotton rats (ref. 13).

Studies on the development of live viral vaccines and glycoprotein subunit vaccines against parainfluenza virus infection are being pursued. Clinical trial results with a formalin-inactivated PIV types 1,2,3 vaccine demonstrated that this vaccine was not efficacious (refs. 14, 15, 16). Further development of chemically-inactivated vaccines was discontinued after clinical trials with a formalin-inactivated RSV vaccine demonstrated that not only was the vaccine not effective in preventing RSV infection but many of the vaccinees who later become infected with RSV suffered a more serious disease. Most of parainfluenza vaccine research has focused on candidate PIV-3 vaccines (ref. 17) with significantly less work being reported for PIV-1 and PIV-2. Recent approaches to PIV-3 vaccines have included the use of the closely related bovine parainfluenza virus type 3 and the generation of attenuated viruses by cold-adaptation of the virus (refs. 18, 19, 20, 21).

Another approach to parainfluenza virus type 3 vaccine development is a subunit approach focusing on the surface glycoproteins hemagglutinin-neuraminidase (HN) and the fusion (F) protein (refs. 22, 23, 24). The HN antigen, a typical type II glycoprotein, exhibits both haemagglutination and neuraminidase activities and

is responsible for the attachment of the virus to sialic acid containing host cell receptors. The type I F glycoprotein mediates fusion of the viral envelope with the cell membrane as well as cell to cell spread of the virus. It has recently been demonstrated that both the HN and F glycoproteins are required for membrane fusion. The F glycoprotein is synthesized as an inactive precursor (F) which is proteolytically cleaved into disulfide-linked F2 and F1 moieties. While the HN and F proteins of PIV-1, -2 and -3 are structurally similar, they are antigenically distinct. Neutralizing antibodies against the HN and F proteins of one of PIV type are not cross-protective. Thus, an effective PIV subunit vaccine must contain the HN and F glycoproteins from the three different types of parainfluenza viruses. Antibody to either glycoprotein is neutralizing *in vitro*. A direct correlation has been observed between the level of neutralizing antibody titres and resistance to PIV-3 infections in infants. Native subunit vaccines for parainfluenza virus type 3 have investigated the protectiveness of the two surface glycoproteins. Typically, the glycoproteins are extracted from virus using non-ionic detergents and further purified using lectin affinity or immunoaffinity chromatographic methods. However, neither of these techniques may be entirely suitable for large scale production of vaccines under all circumstances. In small animal protection models (hamsters and cotton rats), immunization with the glycoproteins was demonstrated to prevent infection with live PIV-3 (refs. 25, 26, 27, 28, 29).

The HN and F glycoproteins of PIV-3 have also been produced using recombinant DNA technology. HN and F glycoproteins have been produced in insect cells using the baculovirus expression system and by use of vaccinia virus and adenovirus recombinants (refs. 30, 31, 32, 33, 34). In the baculovirus expression system, both full-length and truncated forms of the PIV-3 glycoproteins as well as a chimeric F-HN fusion protein have been expressed. The recombinant proteins have been demonstrated to be protective in small animal models (see WO91/00104, US Application No. 07/773,949 filed November 29, 1991, assigned to the assignee hereof).

Semliki Forest virus (SFV) is a member of the Alphavirus genus in the Togaviridae family. The mature virus particle contains a single copy of a ssRNA genome with a positive polarity that is 5'-capped and 3'-polyadenylated. It functions as an mRNA and naked RNA can start an infection when introduced into cells. Upon infection/transfection, the 5' two-thirds of the genome is translated into a polyprotein that is processed into the four nonstructural proteins (nsP1 to 4) by self cleavage. Once the ns proteins have been synthesized they are responsible for replicating the plus-strand (42S) genome into full-length minus strands (ref. 14). These minus-strands then serve as templates for the synthesis of new plus-strand (42S) genomes and the 26S subgenomic mRNA (ref. 14). This subgenomic mRNA, which is colinear with the last one-third of the genome, encodes the SFV structural proteins.

In 1991 Liljestrom and Garoff (ref. 15) designed a series of expression vectors based on the SFV cDNA

replicon. These vectors had the virus structural protein genes deleted to make the way for heterologous inserts, but preserved the nonstructural coding region for production of the nsP1 to 4 replicase complex.

5 Short 5' and 3' sequence elements required for RNA replication were also preserved. A polylinker site was inserted downstream from the 26S promoter followed by translation stop sites in all three frames. An SpeI site was inserted just after the 3' end of the SFV cDNA  
10 for linearization of the plasmid for use *in vitro* transcription reactions.

Injection of SFV RNA encoding a heterologous protein have been shown to result in the expression of the foreign protein and the induction of antibody in a  
15 number of studies (refs. 16,17). The use of SFV RNA inoculation to express foreign proteins for the purpose of immunization would have several of the advantages associated with plasmid DNA immunization. For example, SFV RNA encoding a viral antigen may be introduced in  
20 the presence of antibody to that virus without a loss in potency due to neutralization by antibodies to the virus. Also, because the protein is expressed *in vivo* the protein should have the same conformation as the protein expressed by the virus itself. Therefore,  
25 concerns about conformational changes which could occur during protein purification leading to a loss in immunogenicity, protective epitopes and possibly immunopotential, could be avoided by plasmid DNA immunization.

30 In copending US Patent Application No. 08/476,397 filed June 7, 1995, assigned to the assignee hereof and



the disclosure of which is incorporated herein by reference (WO96/040945), there is described reference the use of plasmid vectors containing RSV F protein-encoding DNA for DNA immunization against RSV infection.

5 In copending United States Patent Application No. 08/896,500 filed July 18, 1997, assigned to the assignee hereof and the disclosure of which is incorporated herein by reference, there is described the use of plasmid vectors containing RSV G protein-encoding DNA  
10 for DNA immunization against RSV infection.

In my copending United States Patent Application No. 08/923,558, filed September 4, 1997, assigned to the assignee hereof and the disclosure of which is incorporated by reference, I describe a DNA vector using  
15 an alphavirus vector, including Semliki Forest virus vector, containing a DNA sequence encoding a paramyxovirus protein, specifically RSV-F, for making an RNA transcript for immunization.

In WO95/27044, the disclosure of which is  
20 incorporated herein by reference, there is described the use of alphavirus cDNA vectors based on cDNA complementary to the alphavirus RNA sequence. Once transcribed from the cDNA under transcriptional control of a heterologous promoter, the alphavirus RNA is able  
25 to self-replicate by means of its own replicase and thereby amplify the copy number of the transcribed recombinant RNA molecules.

Infection with RSV leads to serious disease. It would be useful and desirable to provide improved  
30 vectors for *in vivo* administration of immunogenic preparations, including vaccines, for protection against

disease caused by RSV and other paramyxoviruses. In particular, it would be desirable to provide vaccines that are immunogenic and protective in humans, including seronegative infants, that do not cause disease enhancement (immunopotentialiation).

#### SUMMARY OF THE INVENTION

The present invention provides novel immunogenic materials and immunization procedures based on such novel materials for immunizing against disease caused by respiratory syncytial virus. In particular, the present invention is directed towards the provision of DNA vaccines against disease caused by infection with paramyxoviridae.

In accordance with one aspect of the present invention, there is provided a vector, comprising a first DNA sequence which is complementary to at least part of an alphavirus RNA genome and having the complement of complete alphavirus RNA genome replication regions to permit *in vivo* replication; a second DNA sequence encoding a paramyxovirus protein or a protein fragment that generates antibodies that specifically react with the paramyxovirus protein, the second DNA sequence being inserted into a region of the first DNA sequence which is non-essential for replication; the first and second DNA sequences being under transcriptional control of a promoter; and a third DNA sequence located adjacent the second DNA sequence to enhance the immunoprotective ability of the paramyxovirus protein when expressed *in vivo* from the vector in a host.

The paramyxovirus protein may be selected from the group consisting of a parainfluenza virus (PIV) and a respiratory syncytial virus (RSV). The PIV protein may be from PIV-1, PIV-2, PIV-3 or PIV-4, particularly the  
5 HN and F glycoproteins of PIV-3. The RSV protein particularly may be the F or G glycoprotein of RSV.

The second DNA sequence may encode a full length RSV F protein, or may encode a RSV F protein lacking the transmembrane anchor and cytoplasmic tail. The  
10 lack of the coding region for the transmembrane anchor and cytoplasmic tail results in a secreted form of the RSV F protein. Alternatively, as described in the aforementioned U.S. Patent Application 08/896,500, the second DNA sequence may encode the full-length RSV-G  
15 protein or a truncated RSV G protein lacking a transmembrane region, resulting in a secreted form of the protein.

The alphavirus preferably is a Semliki Forest virus and the first DNA sequence is the Semliki Forest viral  
20 sequence contained in plasmid pSFVI.

The third nucleotide sequence may comprise a pair of splice sites to prevent aberrant mRNA splicing, *in vivo*, whereby substantially all transcribed mRNA from the vector upon administration encodes the RSV protein.  
25 Such third nucleotide sequence is preferably located between the first nucleotide sequence and the promoter sequence. Such third nucleotide sequence may be that of rabbit  $\beta$ -globin intron II, as shown in Figure 8 of copending U.S. Patent Application No. 08/476,397 (WO  
30 96/040945).

The promoter sequence may be an immediate early cytomegalovirus (CMV) promoter. The human cytomegalovirus Intron A sequence may be provided downstream of the promoter and upstream of the third  
5 nucleotide sequence.

A vector encoding the F protein and provided in accordance with one embodiment of the invention may be specifically pMP44, having the identifying characteristics shown in Figure 1D.

10 The vectors provided herein may be used to immunize a host against RSV infection or disease by *in vivo* expression of RSV F protein or RSV G protein, which may lack a transmembrane region, or other paramyxovirus protein, following administration of the vectors. In  
15 accordance with a further aspect of the present invention, therefore, there is provided a method of immunizing a host against disease caused by infection with respiratory syncytial virus or other paramyxovirus, which comprises administering to the host an effective  
20 amount of a vector provided herein.

The present invention also includes a novel method of using a gene encoding an RSV F or G protein or a fragment of an RSV or G protein capable of generating antibodies which specifically react with RSV F or G  
25 protein to protect a host against disease caused by infection with respiratory syncytial virus, which comprises isolating the gene; operatively linking said gene to a DNA sequence which is complementary to at least part of an alphavirus RNA genome and having the  
30 complement of complete alphavirus RNA genome replication regions in a region of said DNA sequence which is non-

essential for replication to form a vector wherein said gene and DNA sequence are under transcriptional control of a promoter; operatively linking the gene to an immunoprotection enhancing sequence to produce an enhanced immunoprotection by the RSV F or G protein in the host, preferably by introducing the immunoprotection enhancing sequence between the control sequence and the alphavirus sequence; and introducing the vector into the host. A corresponding procedure may be used for other paramyxoviridae.

In addition, the present invention includes a method of producing a vaccine for protection of a host against disease caused by infection with respiratory syncytial virus (RSV), which comprises isolating a first DNA sequence encoding an RSV or G protein, from which the transmembrane anchor and cytoplasmic tail may be absent; operatively linking said first DNA sequence to a second DNA sequence which is complementary to at least part of an alphavirus RNA genome and having the complete alphavirus genome replication regions in a region of said second DNA sequence which is non-essential for replication to form a vector wherein said first and second DNA sequences are under transcriptional control of a promoter; operatively linking the first nucleotide sequence to a third nucleotide sequence to enhance the immunoprotective ability of the RSV F or G protein when expressed *in vivo* from the vector in a host; and formulating the vector as a vaccine for *in vivo* administration. A corresponding procedure may be used for other paramyxoviridae.

The present invention further includes a vaccine for administration to a host, including a human host, produced by the method as well as immunogenic compositions comprising an immunoeffective amount of the  
5 vectors described herein.

#### BRIEF DESCRIPTION OF DRAWINGS

Figures 1A to 1B show a schematic of a procedure of assembly of vector pMP44;

Figures 2A to 2B show a schematic of a procedure of  
10 assembly of vector pMP44;

Figures 3A to 3E contain the nucleotide sequence of plasmid pMP44 (SEQ ID NO:1);

Figure 4 shows the anti-RSV F titres in sera from mice taken 4 weeks after priming and 2 weeks after  
15 boosting;

Figure 5 shows the nucleotide sequence for a synthetic oligonucleotide coding for the hepatitis delta ribozyme (SEQ ID no; 2,3); and

Figures 6A to 6C show the nucleotide sequence for  
20 the SFV EcoRV-SpeI fragment ligated to the ribozyme of Figure 5 (SEQ ID no: 4).

GENERAL DESCRIPTION OF INVENTION

As described above, the present invention, in general, relates to protection of hosts against disease caused by infection by paramyxovirus by DNA immunization using DNA vectors. In particular, the invention is concerned with protection of hosts against disease caused by infection by respiratory syncytial virus (RSV), although not specifically limited thereto. The description which follows refers specifically to employing DNA sequences encoding RSV F or G protein and fragments thereof which generate antibodies which specifically react with RSV F or G protein.

In this application, the terms "RSV F protein" and "RSV G protein" are used to define a full-length RSV F or G protein, including proteins having variations in their amino acid sequences including those naturally occurring in various strain of RSV and those introduced by PCR amplification of the encoding gene while retaining the immunogenic properties, a secreted form of the RSV F or G protein lacking a transmembrane anchor and cytoplasmic tail, as well as fragments capable of generating antibodies which specifically react with RSV F or G protein and functional analogs. In this application, a first protein is a "functional analog" of a second protein if the first protein is immunologically related to and/or has the same function as the second protein. The functional analog may be, for example, a fragment of the protein or a substitution, addition or deletion mutant thereof.

A vector is constructed to contain a first DNA sequence which is complementary to at least part of an

alphavirus RNA genome, specifically Semliki Forest virus, and having the complement of complete alphavirus RNA genome replication regions to permit replication *in vivo*. A second DNA sequence encoding the RSV F or G protein is inserted into a region of the first DNA sequence which is non-essential for replication. The first and second DNA sequences are under transcriptional control of a promoter to permit expression of the RSV protein in a host immunized with the vector.

10 The promoter sequence may be the immediately early cytomegalovirus (CMV) promoter. This promoter is described in ref. 36. Any other convenient promoter may be used, including constitutive promoters, such as, Rous Sarcoma Virus LTRs, and inducible promoters, such as  
15 metallothionine promoter, and tissue specific promoters.

The recombinant vector may include a third nucleotide sequence located adjacent the alphavirus sequence to enhance the immunoprotective ability of the RSV F or G protein when expressed *in vivo* in a host.

20 Such enhancement may be provided by increased *in vivo* expression, for example, by increased mRNA stability, enhanced transcription and/or translation. This additional sequence preferably is located between the promoter sequence and the alphavirus sequence.

25 This enhancement sequence may comprise a pair of splice sites to prevent aberrant mRNA splicing during transcription so that substantially all transcribed mRNA is intact alphavirus RNA encoding a gene of interest, for example, an RSV F protein. Specifically, rabbit  $\beta$ -globin Intron II sequence may provide such splice sites,  
30 as also described in ref. 37.



Additional enhancement may be obtained by, including an additional DNA sequence between the promoter and the enhancer sequence. Such additional DNA sequence may comprise the immediate early  
5 cytomegalovirus Intron A sequence.

The vectors provided herein, when administered to an animal, effect *in vivo* RSV F protein expression, as demonstrated by an antibody response in the animal to which it is administered and the conferring of  
10 protection. As may be seen from the results detailed in the Examples below, the DNA vectors produced a high anti-F IgG antibody titre and confer protection.

In comparison to the vectors described in the aforementioned U.S. Patent Application nos. 08/476,397  
15 and 08/896,500, the vectors described herein provide a protective immune response using a lower dose and less time. In comparison to the vectors described in the aforementioned U.S. Patent Application nos. 08/923,558, 08/896,550 and 08/476,397 using native RSV F, the  
20 vectors described herein produce protective immune response in the absence of pretreatment of the animal model with cardiotoxin, a material known to increase the uptake of DNA and enhance the immune response.

The vector provided herein may also comprise a  
25 fourth nucleotide sequence encoding a further antigen from RSV, an antigen from at least one other pathogen or at least one immunomodulating agent, such as cytokine. Such vector may contain said fourth nucleotide sequence in a chimeric or a bicistronic structure. Alternatively,  
30 vectors containing the fourth nucleotide sequence may be

separately constructed and coadministered to a host, with the DNA vector provided herein.

In addition, there may be provided at the 3'-end of the Simliki Forest virus segment, a hepatitis delta virus ribosyme sequence to ensure proper *in vivo* cleavage at the 3'-end of the Simliki Forest virus sequence. Any other convenient sequence may be employed to achieve this effect.

It is clearly apparent to one skilled in the art, that the various embodiments of the present invention have many applications in the fields of vaccination, diagnosis and treatment of RSV infections. A further non-limiting discussion of such uses is further presented below.

#### 1. Vaccine Preparation and Use

Immunogenic compositions, suitable to be used as vaccines, may be prepared from the RSV F or RSV G genes and other paramyxovirus genes and vectors as disclosed herein. The vaccine elicits an immune response in a subject which includes the production of anti-F or anti-G antibodies. Immunogenic compositions, including vaccines, containing the DNA vector may be prepared as injectables, in physiologically-acceptable liquid solutions or emulsions for polynucleotide administration. The nucleic acid may be associated with liposomes, such as lecithin liposomes or other liposomes known in the art, as a nucleic acid liposome (for example, as described in WO 93/24640, ref. 38) or the DNA vector may be associated with an adjuvant, as described in more detail below. Liposomes comprising cationic lipids interact spontaneously and rapidly with

polyanions such as DNA and RNA, resulting in liposome/nucleic acid complexes that capture up to 100% of the polynucleotide. In addition, the polycationic complexes fuse with cell membranes, resulting in an intracellular delivery of polynucleotide that bypasses the degradative enzymes of the lysosomal compartment. Published PCT application WO 94/27435 describes compositions for genetic immunization comprising cationic lipids and polynucleotides. Agents which assist in the cellular uptake of nucleic acid, such as calcium ions, viral proteins and other transfection facilitating agents, may advantageously be used.

Polynucleotide immunogenic preparations may also be formulated as microcapsules, including biodegradable time-release particles. Thus, U.S. Patent 5,151,264 describes a particulate carrier of a phospholipid/glycolipid/polysaccharide nature that has been termed Bio Vecteurs Supra Moléculaires (BVSM). The particulate carriers are intended to transport a variety of molecules having biological activity in one of the layers thereof.

U.S. Patent 5,075,109 describes encapsulation of the antigens trinitrophenylated keyhole limpet hemocyanin and staphylococcal enterotoxin B in 50:50 poly (DL-lactide-co-glycolide). Other polymers for encapsulation are suggested, such as poly(glycolide), poly(DL-lactide-co-glycolide), copolyoxalates, polycaprolactone, poly(lactide-co-caprolactone), poly(esteramides), polyorthoesters and poly(8-hydroxybutyric acid), and polyanhydrides.

Published PCT application WO 91/06282 describes a delivery vehicle comprising a plurality of bioadhesive microspheres and antigens. The microspheres being of starch, gelatin, dextran, collagen or albumin. This delivery vehicle is particularly intended for the uptake of vaccine across the nasal mucosa. The delivery vehicle may additionally contain an absorption enhancer.

The RSV F or G genes and vectors may be mixed with pharmaceutically acceptable excipients which are compatible therewith. Such excipients may include, water, saline, dextrose, glycerol, ethanol, and combinations thereof. The immunogenic compositions and vaccines may further contain auxiliary substances, such as wetting or emulsifying agents, pH buffering agents, or adjuvants to enhance the effectiveness thereof. Immunogenic compositions and vaccines may be administered parenterally, by injection subcutaneously, intravenously, intradermally or intramuscularly, possibly following pretreatment of the injection site with a local anaesthetic. Alternatively, the immunogenic compositions formed according to the present invention, may be formulated and delivered in a manner to evoke an immune response at mucosal surfaces. Thus, the immunogenic composition may be administered to mucosal surfaces by, for example, the nasal or oral (intragastric) routes. Alternatively, other modes of administration including suppositories and oral formulations may be desirable. For suppositories, binders and carriers may include, for example, polyalkalene glycols or triglycerides. Oral formulations may include normally employed incipients,

such as, for example, pharmaceutical grades of saccharine, cellulose and magnesium carbonate.

The immunogenic preparations and vaccines are administered in a manner compatible with the dosage formulation, and in such amount as will be therapeutically effective, protective and immunogenic. The quantity to be administered depends on the subject to be treated, including, for example, the capacity of the individual's immune system to synthesize the RSV F protein and antibodies thereto, and if needed, to produce a cell-mediated immune response. Precise amounts of active ingredient required to be administered depend on the judgment of the practitioner. However, suitable dosage ranges are readily determinable by one skilled in the art and may be of the order of about 1  $\mu$ g to about 1 mg of the RSV F or G genes and vectors. Suitable regimes for initial administration and booster doses are also variable, but may include an initial administration followed by subsequent administrations.

The dosage may also depend on the route of administration and will vary according to the size of the host. A vaccine which protects against only one pathogen is a monovalent vaccine. Vaccines which contain antigenic material of several pathogens are combined vaccines and also belong to the present invention. Such combined vaccines contain, for example, material from various pathogens or from various strains of the same pathogen, or from combinations of various pathogens.

In particular embodiments of the present invention, the vector comprising a first nucleotide sequence

encoding an F or G protein of RSV may be delivered in conjunction with a targeting molecule to target the vector to selected cells including cells of the immune system.

5       The DNA vectors may be delivered to the host by a variety of procedures, for example, Tang et al. (ref. 39) disclosed that introduction of gold microprojectiles coated with DNA encoding bovine growth hormone (BGH) into the skin of mice resulted in production of anti-BGH  
10 antibodies in the mice, while Furth et al. (ref. 40) showed that a jet injector could be used to transfect skin, muscle, fat and mammary tissues of living animals.

## 2. Immunoassays

      The RSV F or G genes and vectors of the present  
15 invention are useful as immunogens for the generation of anti-F or anti-G antibodies for use in immunoassays, including enzyme-linked immunosorbent assays (ELISA), RIAs and other non-enzyme linked antibody binding assays or procedures known in the art. In ELISA assays, the  
20 vector first is administered to a host to generate antibodies specific to the RSV F or G protein or other paramyxovirus protein. These RSV F- or G-specific antibodies are immobilized onto a selected surface, for example, a surface capable of binding the antibodies,  
25 such as the wells of a polystyrene microtiter plate. After washing to remove incompletely adsorbed antibodies, a nonspecific protein such as a solution of bovine serum albumin (BSA) that is known to be antigenically neutral with regard to the test sample may  
30 be bound to the selected surface. This allows for blocking of nonspecific adsorption sites on the

immobilizing surface and thus reduces the background caused by nonspecific bindings of antisera onto the surface.

The immobilizing surface is then contacted with a sample, such as clinical or biological materials, to be tested in a manner conducive to immune complex (antigen/antibody) formation. This procedure may include diluting the sample with diluents, such as solutions of BSA, bovine gamma globulin (BGG) and/or phosphate buffered saline (PBS)/Tween. The sample is then allowed to incubate for from about 2 to 4 hours, at temperatures such as of the order of about 20° to 37°C. Following incubation, the sample-contacted surface is washed to remove non-immunocomplexed material. The washing procedure may include washing with a solution, such as PBS/Tween or a borate buffer. Following formation of specific immunocomplexes between the test sample and the bound RSV F specific antibodies, and subsequent washing, the occurrence, and even amount, of immunocomplex formation may be determined.

#### Biological Deposits

Certain vectors that contain the gene encoding RSV F protein and referred to herein have been deposited with the American Type Culture Collection (ATCC) located at 10801 University Boulevard, Manassas, VA 20110-2209, U.S.A., pursuant to the Budapest Treaty and prior to the filing of this application.

Samples of the deposited plasmids will become available to the public upon grant of a patent based upon this United States patent application and all restrictions on access to the deposits will be removed

at that time. Non-viable deposits will be replaced. The invention described and claimed herein is not to be limited in scope by plasmids deposited, since the deposited embodiment is intended only as an illustration of the invention. Any equivalent or similar plasmids that encode similar or equivalent antigens as described in this application are within the scope of this invention.

#### Deposit Summary

<u>Plasmid</u>	<u>ATCC Designation</u>	<u>Date Deposited</u>
pMP37	97905	Feb. 27, 1997
pMP42		

#### EXAMPLES

The above disclosure generally describes the present invention. A more complete understanding can be obtained by reference to the following specific Examples. These Examples are described solely for purposes of illustration and are not intended to limit the scope of the invention. Changes in form and substitution of equivalents are contemplated as circumstances may suggest or render expedient. Although specific terms have been employed herein, such terms are intended in a descriptive sense and not for purposes of limitations.

Methods of molecular genetics, protein biochemistry and immunology used but not explicitly described in this disclosure and these Examples are amply reported in the scientific literature and are well within the ability of those skilled in the art.



**EXAMPLE 1**

This Example describes a scheme for construction of a Semliki Forest Virus (SFV) DNA expression vector containing a truncated RSV F gene as outlined in Figures 1A to 1B.

Plasmid VR1012 was restricted with PstI and then made blunt-ended with T4 DNA polymerase. The  $\beta$ -globin Intron II was exised out of vector pSG5 (Stratagene) and ligated into plasmid VR1012 to generate plasmid pIIE. Plasmid pIIE was then restricted with SalI and EcoRV and ligated to a PCR fragment having the nucleotide sequence:

TCGACATGGCGGATGTGTGACATACACGACGCCAAAAGATTTTGTTCAGCT  
CCTGCCACCTCCGCTACGCGAGAGATTAACCAACCCACGATGGCCGCCAAAGT  
GCATGTTGATATTGAGGCTGACAGCCCATTCAAGTCTTTCGAGAAGGCA  
TTTCCGTCGTTTCGAGGTGGAGTCATTGCAGGTCACACCAAATGACCATGCAA  
ATGCCAGAGCATTTTCGCACCTGGCTACCAAATTGATCGAGCAGGAGACTGA  
CAAAGACACACTCATCTTGGAT (SEQ ID no: 7) generated from  
pSFVI with primers SAL-SFV having the nucleotide  
sequence 5'-TCCACCTCCAAGATATCCAAGATGAGTGTG (SEQ ID no:  
5) and ECO-SFV having the nucleotide sequence 5'-  
TCCACCTCCAAGATATCCAAGATGAGTGTG (SEQ ID no: 6). The  
resulting plasmid pMP38 was then restricted with EcoRV  
and BamHI and then dephosphorylated. Plasmid pSFV1  
link (see copending application no. \_\_\_\_\_ (b/o  
1038-766)) was then restricted with SpeI and ligated to  
the hepatitis delta ribozyme (Fig. 5, SEQ ID nos: 2 and  
3). The ligation reaction was then restricted with  
EcoRV to release most of the SFV-RSVF plus ribozyme  
fragment. This fragment was then ligated to  
EcoRV/BamHI restricted pMP38 to produce pMP41.

Example 2

This Example describes an alternative scheme for constructing plasmid pMp44 as outlined in Figure 2.

Plasmid VR1012 was restricted with PstI and then  
5 made blunt-ended with T4 DNA polymerase. The  $\beta$ -globin  
Intron II was excised out of vector pSG5 (Stratagene)  
and ligated into plasmid VR1012 to generate plasmid  
pIIE. Plasmid pIIE was then restricted with SalI and  
EcoRV and ligated to a PCR fragment having the  
10 nucleotide sequence:

TCGACATGGCGGATGTGTGACATACACGACGCCAAAAGATTTTGTTCAGCT  
CCTGCCACCTCCGCTACGCGAGAGATTAACCACCCACGATGGCCGCCAAAGT  
GCATGTTGATATTGAGGCTGACAGCCCATTCATCAAGTCTTTGCAGAAGGCA  
TTTCCGTCGTTGAGGTGGAGTCATTGCAGGTCACACCAAATGACCATGCAA  
15 ATGCCAGAGCATTTTCGCACCTGGCTACCAAATTGATCGAGCAGGAGACTGA  
CAAAGACACACTCATCTTGGAT (SEQ ID no: 7) generated from  
pSFVI with primers SAL-SFV having the nucleotide  
sequence 5'-TCCACCTCCAAGATATCCAAGATGAGTGTG (SEQ ID no:  
5) and ECO-SFV having the nucleotide sequence 5'-  
20 TCCACCTCCAAGATATCCAAGATGAGTGTG (SEQ ID no: 6). The  
resulting plasmid pMP38 was then restricted with EcoRV  
and BamHI and then dephosphorylated. Plasmid pSFV1  
link (see copending application no. \_\_\_\_\_ (b/o  
1038-766)) was then restricted with SpeI and ligated to  
25 the hepatitis delta ribozyme (Fig. 5, SEQ ID nos: 2 and  
3).

The ligation reaction product was then restricted  
with EcoRV to release the SFV replicon plus the  
ribozyme having the nucleotide sequence as outlines in  
30 Figures 6A to 6C. This fragment was then ligated to  
the EcoRV/BamHI restricted pMP38 to produce pMP42. The

RSV F gene fragment was released from pMP37 by restriction with BamHI, and this fragment was ligated into the BamHI site of pMP42 to produce pMP44. The nucleotide sequence of pMP44 is shown in Figures 3A to 3E.

### EXAMPLE 3

This Example describes the immunization of mice with pMP44 and the immunogenicity results obtained.

BALB/C mice were immunized with plasmid pMP44 by the intramuscular (i.m.) route. The anterior tibialts muscles of six BALB/C mice were bilaterally injected with 2 x 100  $\mu$ g of plasmid pMP44. This amount is equivalent to approximately 94 $\mu$ g of a conventional vector, based on copy number. These mice were boosted in an identical manner 4 weeks later. The control group was immunized with 2 x 25  $\mu$ g of SFV-RSV F RNA as described in my aforementioned United States Application No. 08/923,558, except that the muscles were not pre-treated with cardiotoxin. The immunization protocol is set forth in the following Table I:

Table 1 Immunization protocol

Group	Prime	Route of Inoculation	Boost	Route of Inoculation
25	1 SFV-RSVF RNA <sup>1</sup>	Intramuscular	SFV-RSVF RNA <sup>1</sup>	Intramuscular
	2 pMP44 DNA <sup>2</sup>	Intramuscular	pMP44DNA <sup>2</sup>	Intramuscular

Mice were inoculated with:

1. 25 $\mu$ g of RNA was injected into each hind leg muscle in 50  $\mu$ L of PBS
2. 100  $\mu$ g of DNA was injected into each hind leg muscle in 50 $\mu$ L of PBS

Sera was obtained from the mice at 4 and 6 weeks. Anti-RSV F antibody titres (IgG) in these sera were determined by enzyme-linked immunosorbent assay (ELISA), as described in Example 3.

5 The anti-RSV F IgG antibody response in the sera of the BALB/C mice are summarized in Figure 4. The mice immunized with the DNA construct, pMP44, had higher anti-F titres than the mice immunized with the SFV-RSV F RNA.

10 Two weeks after the second immunization, mice were challenged intranasally with  $10^6$  plaque forming units (pfu) of the A1 strain of RSV (BG-4A). Animals were sacrificed 4 days later. Lungs were aseptically removed, weighed, and homogenized in 2 mL of complete  
15 culture medium. The virus titre in lung homogenates was determined in duplicate using vero cells, as previously described (ref. 41).

As seen in Table 2 below, immunization of mice with pMP44 DNA protected mice (5/6) against live RSV  
20 challenge, in contrast to the lack of protection when immunization with SFV-RSV F RNA was effected. This result contrasts with the complete protection which is obtained using SFV-RSV F RNA as described in U.S. Patent Application Nos. 08/923,558, 08/476,397 and  
25 08/896,500 where the results show protection after pretreatment with cardiotoxin.

Table 2

Group	Immunogen		Mean Virus Lung Titre	
	Prime	Boost	(log <sub>10</sub> /g±s.d)	% Protection
1	SFV-RSVF RNA	SFV-RSVF RNA	4.26	0
2	pMP44 DNA	pMP44DNA	2.12*	83

\* Limit of detection = 1.8

#### EXAMPLE 4

This Example describes the determination of anti-  
5 RSV F antibody titres.

Nunc-MaxiSorp plate wells were coated overnight at room temperature with 2.5 ng of immunoaffinity-purified RSV F protein diluted in 0.05M carbonate-bicarbonate buffer, pH 9.6. Wells were blocked for non-specific  
10 binding by adding 0.1% BSA in PBS for 30 min. at room temperature, followed by two washes in a washing buffer of 0.1% BSA in PBS + 0.1% Tween 20. Serial two or four-fold dilutions of mouse serum was added to the wells. After a one hour incubation at room  
15 temperature, plates were washed five times with washing buffer, and horseradish peroxidase (HRP) labeled conjugate was added at the appropriate optimal dilution in washing buffer. The total IgG assay used F(ab')<sub>2</sub> goat antimouse IgG (H+L specific)- HRP from Jackson  
20 Immuno Research Laboratory Inc. (Baltimore, MD, USA). Sheep anti-mouse IgG1-HRP from Serotec (Toronto, Ontario, Canada) was used in the IgG1 assay and goat anti-mouse IgG2a from Caltag Laboratories (San Francisco, CA, USA) was used in the IgG2a assay.  
25 Following one hour incubation at room temperature, the plates were washed five times with washing buffer, and hydrogen peroxide (substrate) in the presence of tetramethylbenzidine was added. The reaction was stopped by adding 2 M sulfuric acid. The colour was  
30 read in a Multiscan Titertek plate reader at an optical density (OD) of 450 nm. The titre was taken as the reciprocal of the last dilution at which the OD was

approximately double. This OD must be greater than the negative control of the assay at the starting dilution. The pre-immune serum of each animal was used as the negative control.

5

SUMMARY OF THE DISCLOSURE

In summary of this disclosure, the present invention provides certain novel alphavirus derived DNA vectors containing genes encoding RSV F or RSV G proteins, or other paramyxovirus proteins, methods of immunization using such vectors and methods of diagnosis using such vectors. Modifications are possible within the scope of this invention.

10

REFERENCES

1. McIntosh K. and Chanock R.M. in Fields B.N. and Knipe D.M. (eds). Virology. Raven Press, New York, 1990, pp.1045-1072.  
5
2. Murphy B.R., Hall S.L., Kulkarni A.B., Crowe J.E., Collins P.L., Connors M., Karron R.A. and Chanock R.M., Virus Res 32, 13-36, 1994.  
10
3. Osterweil D. and Norman D., Am Geriat Soc 36, 659-662, 1990.
4. Agius G., Dindinand G., Biggar R.J., Peyre R., Vaillant V., Ranger S., Poupet J.Y., Cisse M.F. and Casters M., J Med Virol 30, 117-127, 1990.  
15
5. Katz S.L. in New vaccine development establishing priorities Vol 1. National Academic Press, Washington, 1985, pp. 3974 09.  
20
6. Wertz G.W. and Sullender W.M., Biotechnology 20, 151-176, 1992 .
7. Fulginiti V.A., Eller J.J., Sieber O.F., Joyner J.W., Minamitani M. and Meiklejohn G., Am J Epidemiol 89, 449-463, 1969.  
25
8. Chin J., Magoffin R.L., Shearer I.A., Schieble J.H. and Lennette E.H., Am J Epidemiol 89, 449-463, 1969.  
30
9. Belshe R.B., Van Voris L.P. and Mufson M.A., J Infect Dis 145, 311-319, 1982.  
35
10. Kim R.M., Arrobio J.O., Pyles G., Brandt C.D., Camargo E., Chanock R.M. and Parrott R.H., Pediatrics 48, 745-755, 1971.
11. Gruber C. and Levine S., J Gen Virol 64, 825-832, 1983.  
40
12. Olmstead R.A., Elango N. and Prince G.A., Proc Natl Acad Sci USA 83, 7462-7466, 1991.  
45

13. Parrington M., Cockle S., Wyde P., Du R.-P., Snell E., Yan W.-Y., Wang Q., Gisonni L., Sanhueza S., Ewasyshyn M. and Klein M., *Virus Genes* 14, 65-74, 1997
- 5 14. Fulginiti, V.A., Eller, J.J., Sieber, O.F., Joyner, J.W., Minamitani, M. and Meiklejohn, G. (1969) *Am. J. Epidemiol.* 89 (4), 435-448.
- 10 15. Chin, J., Magoffin, R.L., Shearer, L.A., Schieble, J.H. and Lennette, E.H. (1969) *Am. J. Epidemiol.* 89 (4), 449-463.
- 15 16. Jensen, K.E., Peeler, B.E. and Dulworth, W.G. (1962) *J. Immunol.* 89, 216-226.
- 20 17. Murphy, B.R., Prince, G.A., Collins, P.L., Van Wyke-Coelingh, K., Olmsted, R.A., Spriggs, M.K., Parrott, R.H., Kim, H.-Y., Brandt, C.D. and Chanock, R.M. (1988) *Vir. Res.* 11, 1-15.
- 25 18. Hall, S.L., Sarris, C.M., Tierney, E.L., London, W.T., and Murphy, B.R. (1993) *J. Infect. Dis.* 167, 958-962.
- 30 19. Belshe, R.B., Karron, R.A., Newman, F.K., Anderson, E.L., Nugent, S.L., Steinhoff, M., Clements, M.L., Wilson, M.H., Hall, S.L., Tierney, E.L. and Murphy, B.R. (1992) *J. Clin. Microbiol.* 30 (8), 2064-2070.
- 35 20. Hall, S.L., Stokes, A., Tierney, E.L., London, W.T., Belshe, R.B., Newman, F.C. and Murphy, B.R. (1992) *Vir. Res.* 22, 173-184.
- 40 21. Van Wyke Coelingh, K.L., Winter, C.C., Tierney, E.L., London, W.T. and Murphy, B.R. (1988) *J. Infect. Dis.* 157 (4), 655-662.
22. Ray, R., Novak, M., Duncan, J.D., Matsuoka, Y. and Compans, R.W. (1993) *J. Infect. Dis.* 167, 752-755.
23. Ray, R., Brown, V.E. and Compans, R.W. (1985) *J. Infect. Dis.* 152 (6), 1219-1230.
- 45 24. Ray, R. and Compans, R.W. (1987) *J. Gen. Virol.* 68, 409-418.



25. Ray, R., Glaze, B.J., Moldoveanu, Z. and Compans, R.W. (1988) J. Infect. Dis. 157 (4), 648-654.
- 5 26. Ray, R., Matsuoka, Y., Burnett, T.L., Glaze, B.J. and Compans, R.W. (1990) J. Infect. Dis. 162, 746-749.
- 10 27. Ray, R., Glaze, B.J. and Compans, R.W. (1988) J. Virol. 62 (3), 783-787.
28. Ewasyshyn, M., Caplan, B., Bonneau A.-M., Scollard, N., Graham, S., Usman, S. and Klein, M. (1992) Vaccine 10 (6), 412-420.
- 15 29. Ambrose, M.W., Wyde, P.R., Ewasyshyn, M., Bonneau, A.-M., Caplan, B., Meyer, H.L. and Klein, M. (1991) Vaccine 9, 505-511.
- 20 30. Kasel, J.A., Frank, A.L., Keitel, W.H., Taber, L.H., Glezen W.P. J. Virol. 1984; 52:828-32.
- 25 31. Lehman, D.J., Roof, L.L., Brideau, R.J., Aeed, P.A., Thomsen, D.R., Elhammer, A.P., Wathen, M.W. and Homa, F.L. (1993) J. Gen. Virol. 74, 459-469.
32. Brideau, R.J., Oien, N.L., Lehman, D.J., Homa, F.L. and Wathen, M.W. (1993) J. Gen. Virol. 74, 471-477.
- 30 33. Ebata, S.N., Prevec, L., Graham, F.L. and Dimock, K. (1992) Vir. Res. 24, 21-33.
- 35 34. Hall, S.L., Murphy, B.R. and Van Wyke Coelingh, K.L. (1991) Vaccine 9, 659-667.
- 35 35. Strauss E.G. and Strauss J.H., in Schlesinger S.S. and Schlesinger M.i. (eds). The Togaviridae and Flaviviridae. Plenum Press, New York, 1986, pp.35-90.
- 40 36. Chapman, B.S.; Thayer, R.M.; Vincent, K.A. and Haigwood, N.L., Nucl. Acids. Res. 1991, 19: 3979-3986.
- 45 37. Breathnack, R. and Harris, B.A., Nucl. Acids Res. 1983, 11: 7119-7136

38. Nabel, G.J. 1993, Proc. Natl. Acad. Sci. USA 90:  
11307-11311.
- 5 39. Tang et al., Nature 1992, 356: 152-154
40. Furth et al. Analytical Biochemistry, 1992, 205:  
365-368
- 10 41. Prince, G.A. et al, Am. J. Pathol. 93, 771 to 790,  
1978.

CLAIMS

What we claim is:

1. A vector, comprising:
  - 5 a first DNA sequence which is complementary to at least part of an alphavirus RNA genome and having the complement of complete alphavirus RNA genome replication regions to permit *in vivo* replication; and
  - a second DNA sequence encoding a paramyxovirus
  - 10 protein or a protein fragment that generates antibodies that specifically react with the paramyxovirus protein, the second DNA sequence being inserted into a region of the first DNA sequence which is non-essential for replication, the first and second DNA sequences being
  - 15 under transcriptional control of a promoter.
2. The vector of claim 1 wherein the paramyxovirus protein is selected from the group consisting of a parainfluenza virus (PIV) and a respiratory syncytial
- 20 virus (RSV).
3. The vector of claim 2 wherein the PIV protein is selected from the group consisting of PIV-1, PIV-2, PIV-3 and PIV-4
- 25
4. The vector of claim 3 wherein said PIV protein is selected from the group consisting of the HN and F glycoproteins of PIV-3.

5. The vector of claim 4 wherein the RSV protein is selected from the group consisting of the F or G glycoprotein of RSV.
- 5 6. The vector of claim 1 wherein the second DNA sequence encodes a full length RSV F or RSV G proteins.
7. The vector of claim 1, wherein the second nucleotide sequence encodes a truncated RSV F or RSV G  
10 protein lacking the transmembrane anchor and cytoplasmic tail.
8. The vector of claim 1 wherein the alphavirus is a Semliki Forest virus.
- 15 9. The vector of claim 1 wherein the first DNA sequence is the Semliki Forest viral sequence contained in plasmid pSFVI.
- 20 10. The vector of claim 1 wherein the promoter sequence is an immediate early cytomegalovirus (CMV) promoter.
11. The vector of claim 1 further comprising a third DNA sequence located adjacent the second DNA sequence  
25 to enhance the immunoprotective ability of the paramyxovirus protein when expressed *in vivo* from the vector in a host.
12. The vector of claim 11 wherein the third nucleotide  
30 sequence comprises a pair of splice sites to prevent aberrant mRNA splicing, *in vivo* whereby substantially

35

all transcribed mRNA from the vector region  
administration encodes the RSV protein.

13. The vector of claim 12 wherein the third nucleotide  
5 sequence is located between the first nucleotide  
sequence and the promoter sequence.

14. The vector of claim 13 wherein said third  
nucleotide sequence is that of rabbit  $\beta$ -globin intron  
10 II.

15. The vector of claim 10 wherein said promoter  
sequence is an immediate early cytomegalovirus (CMV)  
promoter and the human cytomegalovirus Intron A  
15 sequence is provided downstream of the promoter and  
upstream of the third nucleotide sequence.

16. The vector of claim 15 further comprising a fourth  
nucleotide sequence at the 3'-end of the first  
20 nucleotide sequence to to ensure proper *in vivo* cleavage  
at the 3'-end of the first nucleotide sequence.

17. The vector of claim 16 wherein said fourth  
nucleotide sequence is a hepatitis delta virus ribozyme  
25 sequence.

18. The vector of claim 1 which has the identifying  
characteristics of plasmid pMP44 shown in Figure 2D.

30 19. The vector of claim 1 which has SEQ ID No: 1.

20. A method of immunizing a host against disease caused by infection with paramyxovirus, which comprises administering to the host an effective amount of a vector as claimed in claim 1.

5

21. The method of claim 21 wherein said vector has the identifying characteristics of plasmid pMP44 shown in Figure 2D.

10 22. The method of claim 21 wherein said vector has SEQ ID no: 1.

23. A method of using a gene encoding an RSV F or G protein or a fragment of an RSV or G protein capable of  
15 generating antibodies which specifically react with RSV F or G protein to protect a host against disease caused by infection with respiratory syncytial virus, which comprises:

isolating said gene;

20 operatively linking said gene to a DNA sequence which is complementary to at least part of an alphavirus RNA genome and having the complement of complete alphavirus RNA genome replication regions in a region of said DNA sequence which is non-essential for replication  
25 to form a vector wherein said gene and DNA sequence are under transcriptional control of a promoter; and

introducing the vector into the host.

24. The method of claim 23 wherein said gene encoding  
30 an RSV F protein encodes an RSV F protein lacking the transmembrane region.

25. The method of claim 24 wherein said promoter comprises the immediate early cytomegalovirus promoter.

5 26. The method of claim 25 including the step of:  
operatively linking said gene to an immunoprotective enhancing sequence to produce an enhanced immunoprotection to said RSV F protein in said host.

10

27. The method of claim 26 wherein said immunoprotective enhancing sequence is introduced into said vector between said control sequence and said gene.

15 28. The method of claim 27 wherein said immunoprotection enhancing sequence comprises a pair of splice sites to prevent aberrant mRNA splicing whereby substantially intact transcribed mRNA encodes an RSV F protein.

20

29. The method of claim 28 wherein said immunoprotection enhancing sequence is that of rabbit  $\beta$ -globin intron II.

25 30. The method of claim 23 wherein said vector is plasmid pMP44.

31. The vector of claim 23 wherein said vector has SEQ ID no: 1.

30

38

32. A method of producing a vaccine for protection of a host against disease caused by infection with respiratory syncytial virus (RSV), which comprises:

isolating a first DNA sequence encoding an RSV or G protein, from which the transmembrane anchor and cytoplasmic tail may be absent;

operatively linking said first DNA sequence to a second DNA sequence which is complementary to at least part of an alphavirus RNA genome and having the complete alphavirus genome replication regions in a region of said second DNA sequence which is non-essential for replication to form a vector wherein said first and second DNA sequences are under transcriptional control of a promoter; and

formulating the vector as a vaccine for *in vivo* administration.

33. The composition of claim 32 wherein said vector has the identifying characteristics of pMP44 shown in Figure 2D.

34. The method of claim 32 wherein said vector has SEQ ID no: 1.

35. A vaccine for administration to a host, including a human host, produced by the method of claim 32.

36. An immunogenic composition comprising an immunoeffective amount of a vector of claim 1.

30



39

37. The composition of claim 36 wherein said vector has the identifying characteristic of pMP44 in Figure 2D.

38. The composition of claim 36 wherein said vector has

5 SEQ ID no: 1.

1/16

<sup>41</sup>  
Figure 4 Construction of pMP44




Fig. 4-10

2/16





Fig 1B

3/16



+ Bam HI fragments  
from pMP37



Lipid



Fig 1C




FIG 10

5/16


**Figure 1 Construction of pMP44**

fig. 2A

6/16




Fig. 2A

**Figure 2** Nucleotide sequence of plasmid pMP44

```

tcgcgcgttt  cggatgatgac  ggtgaaaacc  tctgacacat  gcagctcccc  gagacgggtca  60
cagcttgtct  gtaagcggat  gccgggagca  gacaagcccc  tcagggcgcg  tcagcgggtg  120
ttggcgggtg  tcggggcttg  ctttaactatg  cggcatcaga  gcagattgta  ctgagagtgc  180
accatatgcg  gtgtgaaata  ccgcacagat  gcgtaaggag  aaaataccgc  atcagattgg  240
ctattggcca  ttgcatacgt  tgtatccata  tcataatatg  tacatttata  ttggctcatg  300
tccaacatta  ccgccatgtt  gacattgatt  attgactagt  tattaatagt  aatcaattac  360
ggggtcatta  gttcatagcc  catatatgga  gttccgcgtt  acataactta  cggtaaatgg  420
cccgcctggc  tgaccgcca  acgaccccc  cccattgacg  tcaataatga  cgtatgttcc  480
catagtaacg  ccaataggga  ctttccattg  acgtcaatgg  gtggagtatt  tacggtaaag  540
tgcccaactg  gcagtacatc  aagtgtatca  tatgccaaag  acgcccccta  ttgacgtcaa  600
tgacggtaaa  tggcccgctt  ggcattatgc  ccagtacatg  accttatggg  actttcctac  660
ttggcagtag  atctacgtat  tagtcatcgc  tattaccatg  gtgatgcggt  ttggcagtag  720
catcaatggg  cgtggatagc  gggtttgactc  acggggattt  ccaagtctcc  acccattac  780
cgtcaatggg  agtttgtttt  ggcacaaa  tcaacgggac  tttccaaaat  gtcgtaacaa  840
ctccgcccc  ttgacgcaa  tgggcggtag  gcgtgtacgg  tgggaggtct  atataagcag  900
agtcgttta  gtgaaccgtc  agatcgctg  gagacgccat  ccacgctgtt  ttgacctca  960
tagaagacac  cgggaccgat  ccagcctccg  cggccgggaa  cgggtgcattg  gaacgcggat  1020
tccccgtgcc  aagagtgcg  taagtaccgc  ctatagactc  tataggcaca  cccctttggc  1080
tcttatgcat  gctatactgt  ttttggctg  gggcctatac  acccccgctt  ccttatgcta  1140
taggttagtg  tatagcttag  cctatagggt  tgggttattg  accattattg  accactcccc  1200
tattggtgac  gatactttcc  attactaatc  cataacatgg  ctctttgcca  caactatctc  1260
tattggctat  atgccaatac  tctgtccttc  agagactgac  acggactctg  tattttttaca  1320
ggatggggtc  ccatattatta  tttaaaaatt  cacatatata  acaacgcggt  ccccggtgcc  1380
cgagttttt  attaaacata  gcgtgggatc  tccacgcgaa  tctcgggtac  gtgttccgga  1440
catgggctct  tctccggtag  cggcggagct  tccacatccg  agccctggtc  ccatgcctcc  1500
agcggctcat  ggtcgctcgg  cagctccttg  ctcctaacag  tggaggccag  acttaggcac  1560
agcacaatgc  ccaccaccac  cagtgtgccc  cacaaggccg  tggcggtagg  gtatgtgtct  1620
gaaaatgagc  gtggagattg  ggctcgcacg  gctgacgcag  atggaagact  taaggcagcg  1680
gcagaagaag  atgcaggcag  ctgagttgtt  gtattctgat  aagagtcaga  ggtaactccc  1740
gttgcggtgc  tgtaaacggt  ggagggcagt  gtagtctgag  cagtactcgt  tgctgccgcg  1800
cgcgcacca  gacataatag  ctgacagact  aacagactgt  tcctttccat  gggctctttc  1860
cgatcctgag  aacttcaggg  tgagtttggg  gaccttgat  tgttctttct  ttttcgctat  1920
tgtaaaattc  atgttatatg  gagggggcaa  agttttcagg  gtgttgttta  gaaagggaag  1980
atgtcccttg  tatcaccatg  gacctcatg  ataattttgt  ttctttcact  ttctactctg  2040
ttgacaacca  ttgtctcctc  ttattttctt  ttcattttct  gtaacttttt  cgttaaaactt  2100
tagcttgcac  ttgtaacgaa  tttttaaatt  cacttttggt  tatttgtcag  attgtaagta  2160
ctttctctaa  tcactttttt  ttcaaggcaa  tcagggtata  ttatattgta  cttcagcaca  2220
gttttagaga  acaattgtta  taattaaatg  ataaggtaga  atatttctgc  atataaattc  2280
tggctggcgt  ggaaatattc  ttattgtag  atcctgggtc  tcactctgcc  2340
tttctcttta  tggttacaat  gatatacact  gtttgagatg  aggataaaat  actctgagtc  2400
caaaccgggc  ccctctgcta  accatgttca  tgccttcttc  ttttctctac  agctcctggg  2460
caacgtgctg  gttattgtgc  tgtctcatca  ttttggcaaa  gaattgtaat  acgactcact  2520
atagggcgaa  ttgtcaccgt  cgtcgacatg  gcggtatgtg  gacatacacg  acgcaaaaag  2580
attttgttcc  agctcctgcc  acctccgcta  cgcgagagat  taaccaccca  cgatggccgc  2640
caaagtgcac  gttgatattg  aggtgcagag  cccattcatc  aagtctttgc  agaaggcatt  2700
tccgtgcttc  gaggtggagt  cattgcaggt  cacaccaaat  gacctgcaa  atgccagagc  2760
attttcgcac  ctggctacca  aattgatcga  gcaggagact  gacaaagaca  cactcatctt  2820
ggatatcggc  agtgcgcctt  ccaggagaat  gatgtctacg  cacaaatacc  actgcgtatg  2880
ccctatgcgc  agcgagaag  accccgaaag  gctcgatagc  tacgcaaaga  aactggcagc  2940
ggcctccggg  aaggtgctgg  atagagagat  cgcaggaaaa  atcaccgacc  tgcagaccgt  3000
catggctacg  ccagacgctg  aatctcctac  cttttgcctg  catacagacg  tcacgtgtcg  3060
tacggcagcc  gaagtggccg  tataccagga  cgtgtatgct  gtacatgcac  caacatcgct  3120
gtaccatcag  gcgatgaaag  gtgtcagaac  ggcgtattgg  attgggtttg  acaccacccc  3180
gtttatgttt  gacgcgctag  caggcgcgta  tccaacctac  gccacaaact  gggccgacga  3240

```



gcaggtgtta	caggccagga	acataggact	gtgtgcagca	tccttgactg	aggggaagact	3300
cggaactg	tccattctcc	gcaagaagca	attgaaacct	tgcgacacag	tcattgtctc	3360
ggtaggatct	acattgtaca	ctgagagcag	aaagctactg	aggagctggc	acttaccctc	3420
cgtattccac	ctgaaaggta	aacaatcctt	tacctgtagg	tgcgatacca	tcgtatcatg	3480
tgaagggtac	gtagttaaga	aaatcactat	gtgccccggc	ctgtacggta	aaacggtagg	3540
gtacgccgtg	acgtatcacg	cggagggtatt	cctagtgtgc	aagaccacag	acactgtcaa	3600
aggagaaaga	gtctcattcc	ctgtatgcac	ctacgtcccc	tcaaccatct	gtgatcaaat	3660
gactggcata	ctagcgaccg	acgtcacacc	ggaggacgca	cagaagttgt	tagtgggatt	3720
gaatcagagg	atagttgtga	acggaagaac	acagcgaaac	actaacacga	tgaagaacta	3780
tctgcttccg	attgtggccg	tcgcatttag	caagtggcg	agggaatata	aggcagacct	3840
tgatgatgaa	aaacctctgg	gtgtccgaga	gaggtcactt	acttgctgct	gcttgtgggc	3900
atttaaaacg	aggaagatgc	acaccatgta	caagaaacca	gacaccacga	caatagtga	3960
gggtccttca	gagtttaact	cgttcgtcat	cccgaagccta	tgggtctacag	gcctcgcaat	4020
cccagcatta	tcacgcatta	agatgctttt	ggccaagaag	accaagcgag	agtttaatac	4080
tgttctcgac	gcgtcgtcag	ccagggatgc	tgaaacaagag	gagaaggaga	gggtggaggc	4140
cgagctgact	agagaagcct	taccaccctt	cgtccccatc	gcgcccggcg	agacgggagt	4200
cgctgcagctc	gacgttgaag	aactagagta	tcacgcaggt	gcaggggtcg	tggaaacacc	4260
tcgcagcgcg	ttgaaagtca	ccgcacagcc	gaacgcagta	ctactaggaa	attacgtagt	4320
tctgtccccg	cagaccgtgc	tcaagagctc	caagttggcc	cccgtgcacc	ctctagcaga	4380
gcaggtgaaa	ataataacac	ataacgggag	ggccggcggt	taccaggtcg	acggatatga	4440
cggaggggtc	ctactacat	gtggatcggc	cctccgggtc	cctgagtttc	aagctttgag	4500
cgagagcgcc	actatggtgt	acaacgaaaag	ggagttcgtc	aacaggaaac	tataccatat	4560
tgccgttcac	ggaccgtcgc	tgaacaccga	cgaggagaac	tacgagaaag	tcagagctga	4620
aagaactgac	gccgagtacg	tgctcgacgt	agataaaaaa	tgctgcgtca	agagagagga	4680
agcgtcgggt	ttggtgttgg	tgggagagct	aaccaacccc	ccgttccatg	aattcgcccta	4740
cgaagggtg	aagatcaggc	cgtcggcacc	atataagact	acagtagtag	gagtccttgg	4800
gggtccggga	tcaggcaagt	ctgctattat	taagagcctc	gtgaccaaac	acgatctggt	4860
caccagcggc	aagaaggaga	actgccagga	aatagttaac	gacgtgaaga	agcaccggcg	4920
gaaggggaca	agtagggaaa	acagtgactc	catectgcta	aacgggtgtc	gtcgtgccgt	4980
ggacatccta	tatgtggacg	aggctttcgc	ttgccattcc	ggtactctgc	tggcccta	5040
tgctcttgtt	aaacctcgga	gcaaagtggg	ggtatgcgga	gaccccaagc	aatgcggatt	5100
cttcaatatg	atgcagctta	aggtgaactt	caaccacaac	atctgactg	aagtatgtca	5160
taaaagtata	tcacagcgtt	gcacgcgtcc	agtcacggcc	atcgtgtcta	cgttcgacta	5220
cggaggcaag	atgcgcacga	ccaacccgtg	caacaaaccc	ataatcatag	acaccacagg	5280
acagaccaag	cccaagccag	gagacatcgt	gttaacatgc	ttccgaggct	gggcaagaca	5340
gctgcagttg	gactaccgtg	gacacgaagt	catgacagca	gcagcatctc	agggcctcac	5400
ccgcaaaggg	gtatacgccg	taaggcagaa	ggtgaatgaa	aatcccttgt	atgccctgc	5460
gtcggagcac	gtgaatgtac	tgctgacgcg	cactgaggat	aggctggtgt	ggaaaacgct	5520
ggccggcgat	ccctggatta	aggtcctatc	aaacattcca	cagggttaact	ttacggccac	5580
attggaagaa	tggcaagaag	aacacgacaa	aataatgaag	gtgattgaag	gaccggctgc	5640
gcctgtggac	gcgttccaga	acaaagcgaa	cgtgtgttgg	gcgaaaagcc	tgggtgcctgt	5700
cctggacact	gccggaatca	gattgacagc	agaggagtgg	agcaccataa	ttacagcatt	5760
taaggaggac	agagcttact	ctccagtggg	ggccttgaat	gaaatttgca	ccaagtacta	5820
tggagttgac	ctggacagtg	gcctgttttc	tgccccgaag	gtgtccctgt	attacgagaa	5880
caaccactgg	gataacagac	ctggtggaag	gatgtatgga	ttcaatgccg	caacagctgc	5940
caggctggaa	gctagacata	ccttcctgaa	ggggcagtg	catacgggca	agcaggcagt	6000
tatcgagaa	agaaaaatcc	aaccgctttc	tgtgtcggac	aatgtaattc	ctatcaaccg	6060
caggctgccg	cacgccctgg	tggctgagta	caagacgggt	aaaggcagta	gggttagagt	6120
gctggtcaat	aaagtaagag	ggtaccacgt	cctgctggtg	agttagtaca	acctggcttt	6180
gcctcgacgc	agggtcactt	ggttgtcacc	gctgaatgtc	acaggcgccg	ataggtgcta	6240
cgacctaaat	ttaggactgc	cggctgacgc	cggcaggttc	gacttgggtct	ttgtgaacat	6300
tcacacggaa	ttcagaatcc	accactacca	gcagtgtgtc	gaccacgcca	tgaagctgca	6360
gatgcttggg	ggagatgcgc	tacgactgct	aaaacccggc	ggcatcttga	tgagagctta	6420
cggatacggc	gataaaatca	gcgaagccgt	tgtttcctcc	ttaagcagaa	agttctcgtc	6480
tgcaagagtg	ttgcgcccgg	attgtgtcac	cagcaatata	gaagtgttct	tgctgttctc	6540
caactttgac	aacggaaaga	gaccctctac	gctacaccag	atgaatacca	agctgagtgc	6600
cgtgtatgcc	ggagaagcca	tgcacacggc	cgggtgtgca	ccatcctaca	gagttaaag	6660

agcagacata	gccacgtgca	cagaagcggc	tgtggttaac	gcagctaabc	cccggtggaac	6720
tgtaggggat	ggcgtatgca	gggccgtggc	gaagaaatgg	ccgtcagcct	ttaaggggagc	6780
agcaacacca	gtgggcacaa	ttaaaacagt	catgtgcggc	tcgtaccccc	tcatccacgc	6840
tgtagcgcct	aattttctctg	ccacgactga	agcggaagg	gaccgcgaat	tggccgctgt	6900
ctaccgggca	gtggccgccc	aagtaaacag	actgtcactg	agcagcgtag	ccatccccgt	6960
gctgtccaca	ggagtgttca	gcggcggaag	agataggctg	cagcaatccc	tcaaccatct	7020
attcacagca	atggacgcca	cggacgctga	cgtgaccatc	tactgcagag	acaaaagtgt	7080
ggagaagaaa	atccaggaag	ccattgacat	gaggacggct	gtggagtgtc	tcaatgatga	7140
cgtggagctg	accacagact	tgggtgagagt	gcacccggac	agcagcctgg	tgggtcgtaa	7200
gggtctacagt	accactgacg	ggctcgctgt	ctcgtacttt	gaaggtacga	aattcaacca	7260
ggctgctatt	gatattggcag	agatactgac	gttggtggccc	agactgcaag	aggcaaacga	7320
acagatatgc	ctatacgcg	tgggcgaaac	aatggacaac	atcagatcca	aatgtccggt	7380
gaacgattcc	gattcatcaa	cacctcccag	gacagtggcc	tgctgtgccc	gctacgcaat	7440
gacagcagaa	cggatcgccc	gccttaggtc	acaccaagtt	aaaagcatgg	tggtttgctc	7500
atcttttccc	ctcccgaat	accatgtaga	tgggtgcag	aaggtaaaagt	gcggtaaagt	7560
tctcctgttc	gacccgacgg	taccttcagt	ggttagtccg	cggaaagtatg	ccgcatctac	7620
gacggaccac	tcagatcggt	cgttacgagg	gtttgacttg	gactggacca	ccgactcgtc	7680
ttccactgcc	agcgatacca	tgtcgctacc	cagtttgacg	tcgtgtgaca	tcgactcgat	7740
ctacgagcca	atggctccca	tagtagtgac	ggctgacgta	cacctgaac	ccgcaggcat	7800
cgcggacctg	gcggcagatg	tgcacctga	acccgcagac	catgtggacc	tcgagaaccc	7860
gattcctcca	ccgcgcccga	agagagctgc	ataccttgcc	tcccgcgagg	cggagcgacc	7920
ggtgcggcgg	ccgagaaagc	cgacgcctgc	cccaaggact	gcgtttagga	acaagctgcc	7980
tttgacgttc	ggcgactttg	acgagcacga	ggtcgatgcg	ttggcctccg	ggattacttt	8040
cggagacttc	gacgacgtcc	tgcgactagg	ccgcgcggtg	gcatatattt	tctcctcgga	8100
cactggcagc	ggacattttac	aacaaaaatc	cgttaggcag	cacaatctcc	agtgcgcaca	8160
actggatgcg	gtccaggagg	agaaaaatga	cccgcacaaa	ttggatactg	agagggagaa	8220
gctgttgctg	ctgaaaatgc	agatgcaccc	atcggaggct	aataagagtc	gataccagtc	8280
tcgcaaaagt	gagaacatga	aagccacggt	ggtggacagg	ctcacatcgg	gggccagatt	8340
gtacacggga	gcggacgtag	gccgcatacc	aacatacgcg	gttcggtacc	cccgcctcgt	8400
gtactcccct	accgtgatcg	aaagattctc	aagccccgat	gtagcaatcg	cagcgtgcaa	8460
cgaataccta	tccagaaatt	acccaacagt	ggcgtcgtag	cagataacag	atgaatacga	8520
cgcatacttg	gacatggttg	acgggtcgga	tagttgcttg	gacagagcga	cattctgccc	8580
ggcgaagctc	cggtgctacc	cgaaacatca	tgctgaccac	cagccgactg	tacgcagatgc	8640
cgtcccgtca	ccctttcaga	acacactaca	gaacgtgcta	gcggccgcca	ccaagagaaa	8700
ctgcaacgtc	acgcaaatgc	gagaactacc	caccatggac	tcggcagtg	tcaacgtgga	8760
gtgcttcaag	cgctatgcct	gctccggaga	atattgggaa	gaatatgcta	aacaacctat	8820
ccggataacc	actgagaaca	tactaccta	tgtgaccaa	ttgaaaggcc	cgaagctgc	8880
tgcttggttc	gctaagaccc	acaacttggt	tccgctgcag	gaggttccca	tggaacagatt	8940
cacggctcag	atgaaacgag	atgtcaaagt	cactccaggg	acgaaacaca	cagaggaaag	9000
acccaaagtc	caggtaattc	aagcagcgga	gccattggcg	accgcttacc	tgtgcggcat	9060
ccacagggaa	ttagtaagga	gactaaatgc	tgtgttacgc	cctaacgtgc	acacattggt	9120
tgatatgtcg	gccgaagact	ttgacgcgat	catcgctct	cacttccacc	caggagaccc	9180
ggttctagag	acggacattg	catcattcga	caaaagccag	gacgactcct	tggctcttac	9240
aggtttaatg	atcctcgaag	atctaggggt	ggatcagtag	ctgctggact	tgatcgaggc	9300
agcctttggg	gaaatatcca	gctgtcacct	accaactggc	acgcgcttca	agttcggagc	9360
tatgatgaaa	tcgggcatgt	ttctgacttt	gtttattaac	actgttttga	acatcaccat	9420
agcaagcagg	gtactggagc	agagactcac	tgactccgcc	tgtgcggcct	tcatcggcga	9480
cgacaacatc	gttcacggag	tgatctccga	caagctgatg	gcggagaggt	gcgcgtcgtg	9540
ggtcaacatg	gaggtgaaga	tcattgacgc	tgatcatggc	gaaaaacccc	catatttttg	9600
tgggggattc	atagtttttg	acagcgtcac	acagaccgcc	tgccgtgttt	cagaccact	9660
taagcgcctg	ttcaagttgg	gtaagccgct	aacagctgaa	gacaagcagg	acgaagacag	9720
gcgacgagca	ctgagtgcag	aggtagcaa	gtggttccgg	acaggcttgg	gggccgaact	9780
ggaggtggca	ctaactcta	ggtatgaggt	agagggtgc	aaaagtatcc	tcatagccat	9840
ggccaccttg	gcgagggaca	ttaaggcgtt	taagaaattg	agaggacctg	ttataccact	9900
ctacggcggt	cctagattgg	tgcgttaata	cacagaattc	tgattggatc	atagcgcact	9960
attataggat	ccgcgcgcgc	gaattcggca	cgagtaacaa	tgaggttgct	aatcctcaaa	10020
gcaaatgcaa	ttaccacaat	cctcactgca	gtcacatttt	gttttgcttc	tggtcaaaac	10080

10/16

```

atcactgaag aattttatca atcaacatgc agtgcagtta gcaaaggcta tcttagtgct 10140
ctgagaactg gttggtatac cagtgttata actatagaat taagtaatat caaggaaaat 10200
aagtgtaatg gaacagatgc taaggtaaaa ttgataaaac aagaattaga taaatataaaa 10260
aatgctgtaa cagaattgca gttgctcatg caaagcacac cagcagcaaa caatcgagcc 10320
agaaggaac taccaagggtt tatgaattat acactcaaca atgccaaaaa aaccaatgta 10380
acattaagca agaaaaaggaa aagaagattt ctctgggtttt tgttaggtgt tggatctgca 10440
atcgccagtg gcgttgctgt atctaaggct ctgcacctag aaggggaagt gaacaagatc 10500
aaaagtgtc tactatccac aaacaaggct gtagtcagct tatcaaattg agttagtgtc 10560
ttaaccagca aagtgttaga cctcaaaaac tatatagata aacaattgtt acctattgtg 10620
aacaagcaaa gctgcagcat atcaaatata gaaactgtga tagagttcca acaaaaagaac 10680
aacagactac tagagattac cagggaattt agtggttaat cagggtgaac tacacctgta 10740
agcacttaca tgttaactaa tagtgaatta ttgtcattaa tcaatgatata gcctataaca 10800
aatgatcaga aaaagttaat gtccaacaat gttcaaatag ttagacagca aagttactct 10860
atcatgtcca taataaaaga ggaagtctta gcatatgtag tacaattacc actatatggt 10920
gttatagata caccctgttg gaaactacac acatcccctc tatgtacaac caacacaaaa 10980
gaagggtcca acatctgttt aacaagaact gacagaggat ggtactgtga caatgcagga 11040
tcagtatctt tcttcccaca agctgaaaca tgtaaagttc aatcaaattc agtattttgt 11100
gacacaatga acagtttaac attaccaagt gaaataaatc tctgcaatgt tgacatattc 11160
aaccctcaaat agattgttaa aattatgact tcaaaaacag atgtaagcag ctccgttattc 11220
acatctctag gagccattgt gtcattgctat ggcaaaaacta aatgtacagc atccaataaa 11280
aatcggtgaa tcataaagac attttctaac ggggtgcgatt atgtatcaaa taaagggatg 11340
gacactgtgt ctgtaggtaa cacattatat tatgtaaata agcaagaagg taaaagtctc 11400
tatgtaaaag gtgaaccaat aataaatttc tatgacccat tagtattccc ctctgatgaa 11460
tttgatgcat caatatctca agtcaacgag aagattaacc agagcctagc atttattcgt 11520
aaatccgatg aattattaca taatgtaaat gctggtaaat ccaccacaaa tatcatgact 11580
tgataatgag gatccagatc ccgggttaatt aattgaatta catccctacg caaacgtttt 11640
acggccgccc gtggcgcccg cgcccggcgg cccgtccttg gccgttgtag gccactccgg 11700
tggtcccggt cgtccccgac ttccaggccc agcagatgca gcaactcatc agcgccgtaa 11760
atgcgctgac aatgagacag aacgcaattg ctccctgtag gcctcccaaa ccaaagaaga 11820
agaagacaac caaaccaaaag ccgaaaacgc agcccaagaa gatcaacgga aaaacgcagc 11880
agcaaaagaa gaaagacaag caagccgaca agaagaagaa gaaacccgga aaaagagaaa 11940
gaatgtgcat gaagattgaa aatgactgta tcttcgtatg cgggtagcca cagtaacgta 12000
gtgtttccag acatgtcggg caccgcacta tcatgggtgc agaaaatctc ggggtgtctg 12060
ggggccttcg caatcggcgc tatcctggtg ctggttgtgg tcaacttgcac tgggtccgc 12120
agataagtta gggtaggcaa tggcattgat atagcaagaa aattgaaaac agaaaaagtt 12180
agggtaagca atggcatata accataaactg tataacttgt aacaaagcgc aacaagacct 12240
gcgcaattgg ccccggtgtc cgccctcacg aaactcgggg caactcatat tgacacatta 12300
attggcaata attggaagct tacataagct taattcgacg aataattgga tttttatttt 12360
attttgcaat tggtttttaa tttttccaaa aaaaaaaaaa aaaaaaaaaa 12420
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaacta gcgggtcggc atggcatctc 12480
cacctcctcg cggtcggacc tgggcatccg aaggaggacg cacgtccact cggatggcta 12540
agggagagat ccagatctgc tgtgccttct agttgccagc catctgttgt ttgcccctcc 12600
cccggtgcct ccttgaccct ggaagggtgcc actcccactg tcctttccta ataaaaatgag 12660
gaaattgcat cgcattgtct gagtaggtgt cattctattc tgggggggtg ggtggggcag 12720
gacagcaagg gggaggattg ggaagacaat agcaggcatg ctggggatgc ggtgggctct 12780
atgggtaccc aggtgctgaa gaattgaccc gggtccctct gggccagaaa gaagcaggca 12840
catccccttc tctgtgacac accctgtcca cgcccctggt tcttagttcc agccccactc 12900
ataggacact catagctcag gagggctccg ccttcaatcc caccgcgtaa agtacttgga 12960
gcggctcttc cctccctcat cagcccacca aaccaaacct agcctccaag agtgggaaga 13020
aattaaagca agataggcta ttaagtgcag agggagagaa aatgcctcca acatgtgagg 13080
aagtaatgag agaaatcata gaatttcttc cgcttccctc ctactgact cgtgcgctc 13140
ggtcggttcg ctgcggcgag cggtatcagc tcaactaaag gcggtaatat ggttatccac 13200
agaatcaggg gataacgcag gaaagaacat gtgagcaaaa ggccagcaaa aggccaggaa 13260
ccgtaaaaag gccgcgttgc tggcggtttt ccataggctc cgccccctg acgagcatca 13320
caaaaatcga cgctcaagtc agaggtggcg aaacccgaca ggactataaa gataccaggc 13380
gtttccccct ggaagctccc tcgtgcgtc tcctgttccg accctgccgc ttaccggata 13440
cctgtccgcc tttctccctt cggaagcgt ggcgtttct catagctcac gctgtaggta 13500

```


6430

11/16

tctcagttcg	gtgtaggtcg	ttcgctccaa	gctgggctgt	gtgcacgaac	cccccgttca	13560
gcccgaaccg	tgcgccttat	ccggtaaacta	tctgtcttgag	tccaacccgg	taagacacga	13620
cttatcgcca	ctggcagcag	ccactggtaa	caggattagc	agagcgaggt	atgtaggcgg	13680
tgctacagag	ttcttgaagt	ggtggcctaa	ctacggctac	actagaagaa	cagtatttgg	13740
tatctgcgct	ctgctgaagc	cagttaccctt	cggaataaaga	ggtggtagct	cttgatccgg	13800
caaacaaacc	accgctggta	gcggtgggtt	ttttgtttgc	aagcagcaga	ttacgcgcag	13860
aaaaaaagga	tctcaagaag	atcctttgat	cttttctacg	gggtctgacg	ctcagtggaa	13920
cgaaaaactca	cgtaagggga	ttttggatcat	gagattatca	aaaaggatct	tcacctagat	13980
ccttttaaat	taaaaaatgaa	gttttaaatc	aatctaaagt	atatatgagt	aaacttggtc	14040
tgacagttac	caatgcttaa	tcagtgaaggc	acctatctca	gcgatctgtc	tatttcggtc	14100
atccatagtt	gcctgactcg	gggggggggg	gcgctgaggt	ctgcctcgtg	aagaaggtgt	14160
tgctgactca	taccaggcct	gaatcgcccc	atcatccagc	cagaaagtga	gggagccacg	14220
gttgatgaga	gctttgttgt	aggtggacca	gttgggtgatt	ttgaactttt	gctttgccac	14280
ggaacggctct	gcgttgctcg	gaagatgcgt	gatctgatcc	ttcaactcag	caaaagtctg	14340
atttattcaa	caaagccgcc	gtcccgtcaa	gtcagcgtaa	tgctctgcca	gtgttacaac	14400
caattaaacca	attgtgatta	gaaaaactca	tcgagcatca	aatgaaactg	caattttattc	14460
atatcaggat	tatcaatacc	atatttttga	aaaagccgtt	tctgtaatga	aggagaaaac	14520
tcaccgaggc	agttccatag	gatggcaaga	tcctgggtatc	gggtctgcgat	tcggactcgt	14580
ccaacatcaa	tacaacctat	taatttcccc	tcgtcaaaaa	taaggttatc	aagtgagaaa	14640
tcaccatgag	tgacgactga	atccggtgag	aatggcaaaa	gcttatgcat	ttctttccag	14700
acttggtcaa	caggccagcc	attacgctcg	tcatacaaat	cactcgcac	aaccaaacccg	14760
ttattcattc	gtgattgcgc	ctgagcgaga	cgaaatacgc	gatcgctgtt	aaaaggacaa	14820
ttacaaacag	gaatcgaatg	caaccggcgc	aggaacactg	ccagcgcac	aacaatattt	14880
tcacctgaat	caggatatte	ttctaatacc	tggaatgctg	ttttcccggg	gatcgagtg	14940
gtgagtaacc	atgcatcatc	aggagtacgg	ataaaatgct	tgatggtcgg	aagaggcata	15000
aattccgtca	gccagtttag	tctgaccatc	tcattctgtaa	catcattggc	aacgctacct	15060
ttgcatgtt	tcagaaacaa	ctctggcgca	tcgggcttcc	catacaatcg	atagattgtc	15120
gcacctgatt	gcccgaacatt	atcgcgagcc	catttatacc	catataaatc	agcatccatg	15180
ttggaattta	atcgcgccct	cgagcaagac	gtttcccgtt	gaatatggct	cataacgttc	15240
cttgatttac	tgtttatgta	agcagacagt	tttattgttc	atgatgat	atgttttatct	15300
tgtgcaatgt	aacatcagag	atgttgagac	acaacgtggc	tttccccccc	ccccattat	15360
tgaagcattt	atcaggggta	ttgtctcatg	agcggatata	tatttgaatg	tatttagaaa	15420
aataaaca	taggggttcc	gcgcacattt	ccccgaaaag	tgccacctga	cgtctaagaa	15480
accattatta	tcattgacatt	aacctataaa	aataggcgta	tcacgaggcc	ctttcgtc	15538

12/16

**Figure 4.** Anti-RSV F titres in sera from mice taken 4 weeks after priming and 2 weeks after boosting



5' CTAGCGGTCGGCATCGCATCTCCACCTCTCGCGGTCCGACCTGGGCATCCGAAGGAGGACGCACGTCCACTCGGATGGCTAAGGGAGA  
GCCAGCCGTACCGTAGAGGTGAGGAGCGCCAGGCTGGACCCGTAGGCTTCCTCCTGCGTGCAGGTAGCCTACCGATTCCCTCTCTAG  
3'

Figure 6 ASFV Eco RV-Spe I fragment ligated to ribozyme

	atcggcagtg	cgccttccag	gagaatgatg	tctacgcaca	aataccactg	cgtatgccct	60
	atgcgcagcg	cagaagaccc	cgaaaggctc	gatagctacg	caaagaaact	ggcagcggcc	120
	tccgggaagg	tgctggatag	agagatcgca	ggaaaaatca	ccgacctgca	gaccgtcatg	180
5	gctacgccag	acgtgaatc	tctacctttt	tgctgcata	cagacgtcac	gtgtcgtacg	240
	gcagccgaag	tggccgtata	ccaggacgtg	tatgtgttac	atgcaccaac	atcgtgttac	300
	catcaggcga	tgaaggtgt	cagaacggcg	tattggattg	ggtttgacac	caccccgttt	360
	atgtttgacg	cgctagcagg	cgcgatatcca	acctacgcca	caaactgggc	cgacgagcag	420
	gtgttacagg	ccaggaacat	aggactgtgt	gcagcactct	tgactgaggg	aagactcggc	480
10	aaactgtcca	ttctccgcaa	gaagcaattg	aaaccttgcg	acacagtcac	gttctcggta	540
	ggatctacat	tgtacactga	gagcagaaaag	ctactgagga	gctggcactt	accctccgta	600
	ttccacctga	aaggtaaaaca	atcctttacc	tgtagggtgcg	ataccatcgt	atcatgtgaa	660
	gggtacgtag	ttaagaaaat	cactatgtgc	cccggcctgt	acggtaaaac	ggtagggtac	720
	gccgtgacgt	atcacgcgga	gggattccta	gtgtgcaaga	ccacagacac	tgtcaaaggga	780
15	gaaagagtct	cattccctgt	atgcacctac	gtccctcaa	ccatctgtga	tcaaattgact	840
	ggcatactag	cgaccgacgt	cacaccggag	gacgcacaga	agttgttagt	gggattgaat	900
	cgagggatag	tgtgaaacg	aagaacacag	cgaaacacta	acacgatgaa	gaactatctg	960
	cttccgattg	tggccgtcgc	atttagcaag	tgggcgagg	aatacaaggc	agaccttgat	1020
	gatgaaaaac	ctctgggtgt	ccgagagagg	tcacttactt	gctgctgctt	gtgggcattt	1080
20	aaaacgagga	agatgcacac	catgtacaag	aaaccagaca	cccagacaat	agtgaagggtg	1140
	ccttcagagt	ttaactcgtt	cgatcatccg	agcctatggt	ctacaggcct	cgcaatccca	1200
	gtcagatcac	gcattaagat	gcttttggcc	aagaagacca	agcgagagtt	aatacctgtt	1260
	ctcgacgcgt	cgtcagccag	ggatgctgaa	caagaggaga	aggagaggtt	ggaggccgag	1320
	ctgactagag	aagccttacc	accctcgtc	cccatcgcg	cggcgagagac	gggagtcgtc	1380
25	gacgtcgacg	ttgaagaact	agagtatcac	gcaggtgcag	gggtcgtgga	aacacctcgc	1440
	agcgcgttga	aagtcaccgc	acagccgaac	gacgtactac	taggaaatta	cgtagttctg	1500
	tccccgcaga	ccgtgctcaa	gagctccaag	ttggccccc	tgcacctct	agcagagcag	1560
	gtgaaaataa	taacacataa	cgaggaggcc	ggcggttacc	aggtcgacgg	atatgacggc	1620
	agggctctac	taccatgtgg	atcgccatt	ccggtccctg	agtttcaagc	tttgagcgag	1680
30	agcgccacta	tggtgtacaa	cgaaaggag	ttcgtcaaca	ggaaactata	ccatattgcc	1740
	gttcacggac	cgtcgctgaa	caccgacgag	gagaactacg	agaaagttag	agctgaaaga	1800
	actgacgccg	agtacgtgtt	cgacgtagat	aaaaaatgct	gcgtcaagag	agaggaagcg	1860
	tcgggtttgg	tgttggtggg	agagctaacc	aacccccgt	tccatgaatt	cgctacgaa	1920
	gggtgaaga	tcaggccgtc	ggcaccatat	aagactacag	tagtaggagt	ctttgggggt	1980
35	ccgggatcag	gcaagtctgc	tattattaag	agcctcgtga	ccaaacacga	tctggtcacc	2040
	agcggaaga	aggagaactg	ccaggaaata	gttaacgacg	tgaagaagca	ccgcgggaag	2100
	gggacaagta	gggaaaacag	tgactccatc	ctgctaaccg	ggtgtcgtcg	tgccgtggac	2160
	atcctatatg	tggacgaggc	tttcgcttgc	cattccggta	ctctgctggc	cctaattgct	2220
	cttggttaaac	ctcggagcaa	agtgggtgta	tgcggagacc	ccaagcaatg	cggtattctt	2280
40	aatatgatgc	agcttaaggt	gaacttcaac	cacaacatct	gcactgaaat	atgtcataaa	2340
	agtatatcca	gacgttgac	gcgtccagtc	acggccatcg	tgtctacgtt	gcactacgga	2400
	ggcaagatgc	gcacgaccaa	cccgtgcaac	aaaccataa	tcatagacac	cacaggacag	2460
	accaagccca	agccaggaga	catcgtgtta	acatgcttcc	gaggctgggc	aaagcagctg	2520
	cagttggact	accgtggaca	cgaagtcatg	acagcagcag	catctcaggg	cctcaccgcg	2580
45	aaaggggtat	acgccgtaag	gcagaagggtg	aatgaaaatc	ccttgtagtc	ccctgcgtcg	2640
	gagcacgtga	atgtactgct	gacgcgcact	gaggataggc	tgggtgtggaa	aacgctggcc	2700
	ggcgatccct	ggattaaggt	cctatcaaac	attccacagg	gtaactttac	ggccacattg	2760
	gaagaatggc	aagaagaaca	cgacaaaata	atgaagggtga	ttgaaggacc	ggctgcgcct	2820
	gtggacgcgt	tccagaacaa	agcgaacgtg	tgttgggcga	aaagcctggg	gcctgtcctg	2880
50	gacactgcgg	gaatcagatt	gacagcagag	gagtggagca	ccataattac	agcatttaag	2940
	gaggacagag	cttactctcc	agtgggtggc	ttgaatgaaa	tttgcaccaa	gtactatgga	3000
	gttgacctgg	acagtggcct	gttttctgcc	ccgaagggtg	ccctgtatta	cgagaacaac	3060
	cactgggata	acagacctgg	tggaggatg	tatggattca	atgccgcaac	agctgccagg	3120
	ctggaagcta	gacatacctt	cctgaagggg	cagtggcata	cgggcaagca	ggcagttatc	3180
55	gcagaaagaa	aaatccaacc	gctttctgtg	ctggacaatg	taattcctat	caaccgcagg	3240
	ctgccgcacg	ccctgggtggc	tgagtacaag	acgggttaaag	gcagtagggt	tgagtggctg	3300
	gtcaataaaag	taagagggtg	ccacgtcctg	ctgggtgagt	agtacaacct	ggctttgcct	3360
	cgacgcaggg	tcacttggtt	gtcaccgctg	aatgtcacag	gcgccgatag	gtgctacgac	3420

Ac.66

	ctaagtttag	gactgccggc	tgacgccggc	aggttcgact	tggctcttgt	gaacattcac	3480
	acggaattca	gaatccacca	ctaccagcag	tgtgtcgacc	acgccatgaa	gctgcagatg	3540
	cttgggggag	atgcgctacg	actgctaaaa	cccgccggca	tcttgatgag	agcttacgga	3600
	tacgccgata	aaatcagcga	agcgtgtgtt	tcctccttaa	gcagaaagtt	ctcgtctgca	3660
5	agagtgttgc	gcccggtatt	tgtcaccagc	aatacagaag	tgttcttgtc	gttctccaac	3720
	tttgacaacg	gaaagagacc	ctctacgcta	caccagatga	ataccaagct	gagtgcogtg	3780
	tatgccggag	aagccatgca	cacggccggg	tgtgcaccat	cctacagagt	taagagagca	3840
	gacatagcca	cgtgcacaga	agcggctgtg	gttaacgcag	ctaaccgccc	tggaaactgt	3900
	ggggatggcg	tatgcagggc	cgtggcgaa	aaatggccgt	cagcctttaa	gggagcagca	3960
10	acaccagtgg	gcacaattaa	aacagtcagt	tgcggctcgt	accccgctcat	ccagctgtga	4020
	gcgcctaatt	tctctgccac	gactgaagcg	gaaggggacc	gcgaattggc	cgctgtctac	4080
	cgggcagtgg	ccgccgaagt	aaacagactg	tcactgagca	gcgtagccat	cccgtgtctg	4140
	tccacaggag	tgttcagcgg	cggaaagagat	aggctgcagc	aatccctcaa	ccatctattc	4200
	acagcaatgg	acgccacgga	cgctgacgtg	accatctact	gcagagacaa	aagtggggag	4260
15	aagaaaatcc	aggaagccat	tgacatgagg	acggctgtgg	agttgctcaa	tgatgacgtg	4320
	gagctgacca	cagacttggg	gagagtgcac	ccggacagca	gcctgggtggg	tcgtaagggc	4380
	tacagtacca	ctgacgggtc	gctgtactcg	tactttgaag	gtacgaaatt	caaccagggt	4440
	gctattgata	tggcagagat	actgacgttg	tggcccagac	tgcaagaggg	aaacgaacag	4500
	atatgcctat	acgcgctggg	cgaacaattg	gacaacatca	gatccaaatg	tcgggtgaac	4560
20	gattccgatt	catcaacacc	tcccaggaca	gtgccctgcc	tgtgccgcta	cgcaatgaca	4620
	gcagaacgga	tcgcccgcct	taggtcacac	caagttaaaa	gcatgggtgg	ttgctcatct	4680
	tttcccctcc	cgaaatacca	tgtagatggg	gtgcagaagg	taaagtgcga	gaaggttctc	4740
	ctgttcgacc	cgacgggtacc	ttcagtgggt	agtccgcgga	agtatgccgc	atctacgacg	4800
	gaccactcag	atcggctcgt	acgagggttt	gacttggact	ggaccacoga	ctcgtcttcc	4860
25	actgccagcg	ataccatgtc	gctaccagct	ttgcagtcgt	gtgacatcga	ctcgatctac	4920
	gagccaatgg	ctcccatagt	agtgcgggtc	gacgtacacc	ctgaaccgcg	aggcatcgcg	4980
	gacctggcgg	cagatgtgca	ccctgaaccc	gcagaccatg	tggacctcga	gaaccggatt	5040
	cctccaccgc	gcccgaagag	agctgcatac	cttgcctccc	gcgcggcgga	gcgaccgggtg	5100
	ccggcgccga	gaaagccgac	gcctgcccc	aggactgcgt	ttaggaacaa	gctgcctttg	5160
30	acgttcggcg	actttgacga	gcacgaggtc	gatgcgttgg	cctccgggat	tactttcgga	5220
	gacttcgacg	acgtcctgcg	actaggccgc	gcgggtgcat	atattttctc	ctcgacactc	5280
	ggcagcggac	atttacaaca	aaaatccgtt	aggcagcaca	atctccagtg	cgcacaactg	5340
	gatgcgggtc	aggaggagaa	aatgtaccgc	ccaaaattgg	atactgagag	ggagaagctg	5400
	ttgctgctga	aaatgcagat	gcacccatcg	gaggcttaata	agagtcgata	ccagtctcgc	5460
35	aaagtggaga	acatgaaagc	cacgggtggtg	gacaggctca	catcgggggc	cagattgtac	5520
	acgggtagcg	acgtaggccg	cataccaaca	tacgcggttc	ggtacccccg	cccggtgtac	5580
	tcccctaccg	tgatcgaaag	attctcaagc	cccgatgtag	caatcgacgc	gtgcaactga	5640
	tacctatcca	gaaattacc	aacagtggcg	tcgtaccaga	taacagatga	atagcagcga	5700
	tacttggaca	tggttgacgg	gtcggatagt	tgcttggaca	gagcagacatt	ctgcccggcg	5760
40	aagctccggt	gctaccgcaa	acatcatgcg	taccaccagc	cgactgtacg	cagtgcctgc	5820
	ccgtcaccct	ttcagaacac	actacagaac	gtgctagcgg	ccgccaccaa	gagaaactgc	5880
	aacgtcacgc	aaatgcgaga	actaccacc	atggactcgg	cagtgttcaa	cgtggagtgc	5940
	ttaagcgct	atgcctgtc	cggagaatat	tgggaagaat	atgctaaca	acctatccgg	6000
	ataaccactg	agaacatcac	tacctatgtg	accaaattga	aaggcccga	agctgtctgc	6060
45	ttgttcgcta	agaccacaa	cttgggttccg	ctgcaggagg	ttcccatgga	cagattcacg	6120
	gtcgacatga	aacgagatgt	caaagtcaact	ccaggagcga	aacacacaga	ggaaagaccc	6180
	aaagtccagg	taattcaagc	agcggagcca	ttggcgaccg	cttacctgtg	cggcatccac	6240
	agggaaattag	taaggagact	aaatgctgtg	ttacgcctta	acgtgcacac	attgtttgat	6300
	atgtcggccg	aagactttga	cgcgatcatc	gcctctcact	tccaccacag	agaccgggtt	6360
50	ctagagacgg	acattgcate	attcgacaaa	agccaggacg	actccttggc	tcttacaggt	6420
	ttaatgatcc	tcgaagatct	aggggtggat	cagtaccctg	tggacttgat	cgaggcagc	6480
	tttggggaaa	tatccagctg	tcacctaaca	actggcacgc	gcttcaagtt	cggagctatg	6540
	atgaaatcgg	gcatgtttct	gactttgttt	attaacactg	ttttgaacat	caccatagca	6600
	agcagggtac	tggagcagag	actcactgac	tccgcctgtg	cggccttcat	cggcgacgac	6660
55	aacatcggtc	acggagtgtg	ctccgacaag	ctgatggcgg	agaggtgcgc	gtcgtgggtc	6720
	aacatggagg	tgaagatcat	tgacgctgtc	atgggcgaaa	aacccccata	tttttgtggg	6780
	ggattcatag	tttttgacag	cgtcacacag	accgcctgcc	gtgtttcaga	cccacttaag	6840
	cgctgttca	agttgggtaa	gccgctaaca	gctgaagaca	agcaggacga	agacaggcga	6900
	cgagcactga	gtgacgaggt	tagcaagtgg	ttccggacag	gcttgggggc	cgaactggag	6960



4160

gtggcactaa catctaggta tgaggtagag ggctgcaaaa gtatccctcat agccatggcc 7020  
 accttggcga gggacattaa ggcgtttaag aaattgagag gacctgttat acacctctac 7080  
 ggcggtccta gattggtgcg ttaatacaca gaattctgat tggatcatag cgcactatta 7140  
 taggatccag atccccgggta attaattgaa ttacatccct acgcaaacgt ttacggyccg 7200  
 5 cgggtggcgc ccgcgcccgg cggcccgtcc ttggccgttg caggccactc cgggtggctcc 7260  
 cgtegtcccc gacttccagg cccagcagat gcagcaactc atcagcgccg taaatgcgct 7320  
 gacaatgaga cagaacgcaa ttgctcctgc taggcctccc aaaccaaaga agaagaagac 7380  
 aaccaaacca aagccgaaaa cgcagcccaa gaagatcaac ggaaaaacgc agcagcaaaa 7440  
 gaagaaagac aagcaagccg acaagaagaa gaagaaaccc ggaaaaagag aaagaatgtg 7500  
 10 catgaagatt gaaaatgact gtatcttcgt atgcggttag ccacagtaac gtagtgtttc 7560  
 cagacatgtc gggcaccgca ctatcatggg tgcagaaaat ctcggtggtt ctgggggcct 7620  
 tcgcaatcgg cgctatcctg gtgctggttg tggtcacttg cattgggtc cgcagataag 7680  
 ttagggtagg caatggcatt gatatagcaa gaaaattgaa aacagaaaaa gttagggtaa 7740  
 gcaatggcat ataaccataa ctgtataact tgtaacaaag cgcaacaaga cctgcgcaat 7800  
 15 tggccccgtg gtccgcctca cggaaactcg gggcaactca tattgacaca ttaattggca 7860  
 ataattggaa gcttacataa gcttaattcg acgaataatt ggatttttat tttattttgc 7920  
 aattggtttt taatatttcc aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 7980  
 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa ctacgggtc ggcatggcat ctccacctcc 8040  
 tcgcggtccg acctgggcat ccgaaggagg acgcacgtcc actcggtg ctaagggaga 8100  
 20

# INTERNATIONAL SEARCH REPORT

Inter. .onal Application No

PCT/CA 98/01064

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/86 C12N15/45 C07K14/135 C07K14/115 A61K31/70

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 96 40945 A (CONNAUGHT LAB ;LI XIAOMAO (CA); EWASYSHYN MARY E (CA); SAMBHARA SU) 19 December 1996 cited in the application see the whole document, especially page 6, lines 2-9; page 14, lines 15-21; and page 23, lines 18-23	1-36
Y	WO 95 27044 A (BIOPTION AB ;LILJESTROEM PETER (SE); GAROFF HENRIK (SE)) 12 October 1995 cited in the application see the whole document, especially page 8, lines 12-22	1-36
A	WO 96 17072 A (VIAGENE INC) 6 June 1996 see the whole document -/--	1-36

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

23 April 1999

Date of mailing of the international search report

03/05/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Mandl, B

# INTERNATIONAL SEARCH REPORT

Inter. Patent Application No

PCT/CA 98/01064

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	ZHOU X. ET AL.: "Self-replicating Semliki-Forest virus RNA as recombinant vaccine" VACCINE, vol. 12, no. 16, 1994, pages 1510-1514, XP002089524 cited in the application see the whole document ---	1-36
A	LILJESTROEM P. ET AL.: "A NEW GENERATION OF ANIMAL CELL EXPRESSION VECTORS BASED ON THE SEMLIKI FOREST VIRUS REPLICON" BIO/TECHNOLOGY, vol. 9, December 1991, pages 1356-1361, XP000616021 cited in the application see the whole document ---	1-36
E,L	WO 99 11808 A (CONNAUGHT LAB ;PARRINGTON MARK (CA)) 11 March 1999  cited in the application see the whole document -----	1-9,20, 23,24, 32,35,36

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/CA 98/00840

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/86 C12N15/45 C07K14/115 C07K14/135 A61K31/70

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 96 40945 A (CONNAUGHT LAB ;LI XIAOMAO (CA); EWASYSHYN MARY E (CA); SAMBHARA SU) 19 December 1996 cited in the application see the whole document ---	1-53
Y	LILJESTROEM P. ET AL.: "A NEW GENERATION OF ANIMAL CELL EXPRESSION VECTORS BASED ON THE SEMLIKI FOREST VIRUS REPLICON" BIO/TECHNOLOGY, vol. 9, December 1991, pages 1356-1361, XP000616021 cited in the application see the whole document ---	1-53
A	US 5 614 372 A (LILJA HANS ET AL) 25 March 1997 see column 5, line 61 - line 65 ---	1-53

-/--



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

### \* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"A" document member of the same patent family

Date of the actual completion of the international search

8 January 1999

Date of mailing of the international search report

22/01/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3018

Authorized officer

Mandl, B

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/CA 98/00840

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	SCHLESINGER S.: "ALPHAVIRUSES - VECTORS FOR THE EXPRESSION OF HETEROLOGOUS GENES" TRENDS IN BIOTECHNOLOGY, vol. 11, no. 1, 1 January 1993, pages 18-22, XP000358625 see page 20, left-hand column, last paragraph - right-hand column, paragraph 1 -----	1-53
A	WO 96 17072 A (VIAGENE INC) 6 June 1996 see the whole document, especially page 38, lines 20-31 and page 61 lines 12-32 -----	1-53
A	ZHOU X. ET AL.: "Self-replicating Semliki-Forest virus RNA as recombinant vaccine." VACCINE, vol. 12, no. 16, 1994, pages 1510-1514, XP002089524 cited in the application see the whole document -----	1-53

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/CA 98/00840

## Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
Remark: Although claim(s) 45-49  
is(are) directed to a method of treatment of the human/animal  
body, the search has been carried out and based on the alleged  
effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such  
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all  
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment  
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report  
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is  
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

**INTERNATIONAL SEARCH REPORT**  
information on patent family members

International Application No  
**PCT/CA 98/00840**

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9640945 A	19-12-1996	AU 695527 B	13-08-1998
		AU 6117696 A	30-12-1996
		CA 2223610 A	19-12-1996
		EP 0832253 A	01-04-1998
		US 5843913 A	01-12-1998
US 5614372 A	25-03-1997	EP 0811164 A	10-12-1997
		WO 9626442 A	29-08-1996
WO 9617072 A	06-06-1996	AU 4594996 A	19-06-1996
		EP 0797679 A	01-10-1997
		US 5814482 A	29-09-1998
		US 5843723 A	01-12-1998
		US 5789245 A	04-08-1998

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/CA 98/01064

## Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
Remark: Although claims 20-30  
are directed to a method of treatment of the human/animal  
body, the search has been carried out and based on the alleged  
effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such  
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all  
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment  
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report  
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is  
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.



# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/CA 98/01064

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9640945 A	19-12-1996	AU 695527 B AU 6117696 A CA 2223610 A EP 0832253 A US 5843913 A US 5880104 A	13-08-1998 30-12-1996 19-12-1996 01-04-1998 01-12-1998 09-03-1999
WO 9527044 A	12-10-1995	AU 699384 B AU 2155795 A CA 2184261 A EP 0753053 A FI 963860 A JP 9511143 T	03-12-1998 23-10-1995 12-10-1995 15-01-1997 27-09-1996 11-11-1997
WO 9617072 A	06-06-1996	AU 4594996 A EP 0797679 A US 5814482 A US 5843723 A US 5789245 A	19-06-1996 01-10-1997 29-09-1998 01-12-1998 04-08-1998
WO 9911808 A	11-03-1999	NONE	